C. David Marsden

Q: What Schools Are Affiliated With C. David Marsden

C. David Marsden is affiliated with the following schools: University of Lausanne, King's College London

C. David Marsden's AcademicInfluence.com Rankings

C. David Marsden

Medical

#97

World Rank

#158

Historical Rank

Neurology

World Rank

#17

Historical Rank

medical Degrees

C. David Marsden

Biology

#760

World Rank

#1316

Historical Rank

Neuroscience

#43

World Rank

#45

Historical Rank

biology Degrees

Download Badge

Medical
Biology

Why Is C. David Marsden Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David Marsden , FRS was a British neurologist who made a significant contribution to the field of movement disorders. He was described as ‘arguably the leading academic neurologist and neuroscientist of his generation in the UK’.

(See a Problem?)

C. David Marsden's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Corticocortical inhibition in human motor cortex. (1993) (2933)
Recent Developments in Parkinson's Disease (1986) (2310)
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE (1989) (1697)
Mitochondrial Complex I Deficiency in Parkinson's Disease (1990) (1640)
Interhemispheric inhibition of the human motor cortex. (1992) (1398)
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease (1989) (1392)
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. (1990) (1171)
Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease (1989) (1111)
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia (1994) (1093)
The behavioural and motor consequences of focal lesions of the basal ganglia in man. (1994) (1025)
The mysterious motor function of the basal ganglia (1982) (998)
Validity and reliability of a rating scale for the primary torsion dystonias (1985) (997)
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. (1991) (976)
Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. (1989) (924)
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. (1992) (884)
Manual motor performance in a deafferented man. (1982) (847)
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. (1988) (846)
Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra (1997) (812)
The pathophysiology of primary dystonia. (1998) (796)
Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. (1995) (733)
The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. (1994) (718)
Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease (1990) (698)
"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY (1976) (674)
Classification of dystonia. (1998) (666)
Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy (1990) (637)
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE (1977) (625)
Human walking and higher‐level gait disorders, particularly in the elderly (1993) (616)
The anatomical basis of symptomatic hemidystonia. (1985) (598)
Internal versus external cues and the control of attention in Parkinson's disease. (1988) (581)
Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease (1992) (542)
Disturbance of sequential movements in patients with Parkinson's disease. (1987) (516)
A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra (1989) (512)
Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. (1995) (499)
Cognitive function in Parkinson's disease: From description to theory (1990) (478)
Physiological and pathological tremors and rhythmic central motor control. (2000) (473)
INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN (1987) (470)
Evidence for long‐term survival and function of dopaminergic grafts in progressive Parkinson's disease (1994) (457)
Motor cortex stimulation in intact man. 1. General characteristics of EMG responses in different muscles. (1987) (452)
Young onset Parkinson's disease (1987) (451)
Mini-mental state examination in neurological patients. (1984) (443)
Writers' cramp-a focal dystonia. (1982) (440)
Effect of vision and stance width on human body motion when standing: implications for afferent control of lateral sway. (1993) (430)
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study (1994) (425)
l-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction (2005) (414)
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs (1980) (413)
Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography (1992) (411)
Motor cortex stimulation in intact man. 2. Multiple descending volleys. (1987) (404)
Performance of simultaneous movements in patients with Parkinson's disease. (1986) (397)
The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. (1990) (396)
Pathophysiology of blepharospasm and oromandibular dystonia. (1985) (394)
Corticobasal degeneration. A clinical study of 36 cases. (1994) (393)
Depression in Parkinson's disease: a quantitative and qualitative analysis. (1986) (393)
Movement disorders following lesions of the thalamus or subthalamic region (1994) (384)
Assessing tremor severity. (1993) (384)
What do the basal ganglia do? (1998) (381)
New observations on the normal auditory startle reflex in man. (1991) (381)
Servo Action in Human Voluntary Movement (1972) (380)
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. (1986) (373)
Fluctuations of disability in Parkinson's disease – clinical aspects (1981) (369)
Transplantation of fetal dopamine neurons in Parkinson's disease: One‐year clinical and neurophysiological observations in two patients with putaminal implants (1992) (367)
Limb apraxias: higher-order disorders of sensorimotor integration. (2000) (365)
Dual task performance and processing resources in normal subjects and patients with Parkinson's disease. (1991) (363)
Short‐ and long‐term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease (1997) (360)
Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. (1992) (359)
A study of hereditary essential tremor. (1994) (353)
Reciprocal inhibition between the muscles of the human forearm. (1984) (341)
Reciprocal inhibition between forearm muscles in patients with writer's cramp and other occupational cramps, symptomatic hemidystonia and hemiparesis due to stroke. (1989) (340)
Tardive dystonia (1982) (339)
HOW COMMON IS DEMENTIA IN PARKINSON'S DISEASE? (1984) (334)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset (1984) (328)
Delay in the execution of voluntary movement by electrical or magnetic brain stimulation in intact man. Evidence for the storage of motor programs in the brain. (1989) (325)
A method of monitoring function in corticospinal pathways during scoliosis surgery with a note on motor conduction velocities. (1986) (324)
Servo action in the human thumb. (1976) (321)
Blepharospasm: a review of 264 patients. (1988) (315)
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease (1994) (315)
Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder (1994) (315)
The function of the antagonist muscle during fast limb movements in man. (1983) (313)
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. (1995) (312)
"Muscular wisdom" that minimizes fatigue during prolonged effort in man: peak rates of motoneuron discharge and slowing of discharge during fatigue. (1983) (307)
Scaling of the size of the first agonist EMG burst during rapid wrist movements in patients with Parkinson's disease. (1986) (302)
A prevalence study of primary dystonia in eight European countries (2000) (302)
Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. (2000) (298)
SCOPE OF A TECHNIQUE FOR ELECTRICAL STIMULATION OF HUMAN BRAIN, SPINAL CORD, AND MUSCLE (1982) (298)
Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms (1998) (296)
Glutathione‐related enzymes in brain in Parkinson's disease (1994) (295)
Stretch reflex and servo action in a variety of human muscles. (1976) (293)
Frequency peaks of tremor, muscle vibration and electromyographic activity at 10 Hz, 20 Hz and 40 Hz during human finger muscle contraction may reflect rhythmicities of central neural firing (1997) (293)
Mitochondrial function in Parkinson's disease (1992) (291)
Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. (1999) (284)
Outcome of Investigation of Patients with Presenile Dementia (1972) (284)
Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia (1995) (283)
The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. (1990) (283)
The Bereitschaftspotential is abnormal in Parkinson's disease. (1989) (283)
New insights into the cause of Parkinson's disease (1992) (282)
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity (1998) (280)
The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. (1988) (279)
Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease (2005) (276)
A positron emission tomography study of essential tremor: Evidence for overactivity of cerebellar connections (1993) (275)
Neurological Anatomy in Relation to Clinical Medicine (3rd Ed.) (1982) (272)
Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia (1992) (272)
Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. (1994) (272)
Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man (2004) (268)
Decreased Ferritin Levels in Brain in Parkinson's Disease (1990) (259)
Complex I, Iron, and ferritin in Parkinson's disease substantia nigra (1994) (244)
Parkinson's disease (1940) (244)
Visuospatial memory deficits at different stages of Parkinson's disease (1993) (243)
Different sites of action of electrical and magnetic stimulation of the human brain (1987) (241)
‘Subcorttcal dementia’: The neuropsychological evidence (1988) (240)
Physiological analysis of simple rapid movements in patients with cerebellar deficits. (1991) (240)
The spectrum of cortical myoclonus. From focal reflex jerks to spontaneous motor epilepsy. (1985) (239)
Control of on/off phenomenon by continuous intravenous infusion of levodopa (1984) (238)
Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? (1976) (238)
Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease (1987) (237)
Single-joint rapid arm movements in normal subjects and in patients with motor disorders. (1996) (235)
Human postural responses. (1981) (234)
Isolated tremor and disruption of the nigrostriatal dopaminergic system (1992) (230)
Percutaneous electrical stimulation of corticospinal pathways at the level of the pyramidal decussation in humans (1991) (228)
The behaviour of the long-latency stretch reflex in patients with Parkinson's disease (1983) (224)
Simple and choice reaction time and the use of advance information for motor preparation in Parkinson's disease. (1992) (223)
Ballistic flexion movements of the human thumb. (1979) (222)
Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei (1977) (219)
Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus) (1995) (219)
Transplantation of fetal dopamine neurons in Parkinson's disease: PET {18F}6‐L‐fluorodopa studies in two patients with putaminal implants (1992) (218)
The Diagnosis of Stupor and Coma, 3rd ed (1981) (217)
The hyperekplexias and their relationship to the normal startle reflex. (1991) (216)
Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. (1977) (214)
The causalgia-dystonia syndrome. (1993) (208)
Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. (1997) (205)
Comparison of executive and visuospatial memory function in Huntington's disease and dementia of Alzheimer type matched for degree of dementia. (1995) (204)
Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. (1977) (203)
Modulation of motor cortical excitability by electrical stimulation over the cerebellum in man. (1991) (202)
Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography (1992) (202)
PAINFUL PARKINSON'S DISEASE (1986) (201)
Changes in the response to magnetic and electrical stimulation of the motor cortex following muscle stretch in man. (1991) (200)
Axial myoclonus of propriospinal origin. (1991) (200)
Idiopathic torsion dystonia (dystonia musculorum deformans). A review of forty-two patients. (1974) (199)
Visuospatial function in Parkinson's disease. (1986) (199)
Slowness of movement in Parkinson's disease (1989) (198)
Autosomal dominant nocturnal frontal-lobe epilepsy: genetic heterogeneity and evidence for a second locus at 15q24. (1998) (195)
Depression and disability in Parkinson's disease: a follow-up of 132 cases (1988) (195)
Long-latency automatic responses to muscle stretch in man: origin and function. (1983) (192)
LIPID PEROXIDATION AS CAUSE OF NIGRAL CELL DEATH IN PARKINSON'S DISEASE (1986) (189)
Dopa‐responsive dystonia (1991) (188)
Cortical reflex myoclonus (1979) (187)
The pedunculopontine nucleus: its role in the genesis of movement disorders. (2000) (187)
Clinical and physiological features of epilepsia partialis continua. Cases ascertained in the UK. (1996) (187)
Torsion dystonia (1986) (187)
The effect of percutaneous motor cortex stimulation on H reflexes in muscles of the arm and leg in intact man. (1986) (184)
The nosology and pathophysiology of myoclonus (1981) (183)
Simple tics in Gilles de la Tourette's syndrome are not prefaced by a normal premovement EEG potential. (1981) (183)
Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. (1991) (180)
Anticipatory postural reflexes in Parkinson's disease and other akinetic-rigid syndromes and in cerebellar ataxia. (1980) (176)
Clinical presentation and pharmacological therapy in corticobasal degeneration. (1998) (174)
Accuracy of self-reported disability in patients with parkinsonism. (1989) (173)
Magnetic stimulation over the spinal enlargements. (1989) (172)
Origins of normal and pathological tremor (1984) (169)
Peripheral beta-adrenergic receptors concerned with tremor. (1967) (168)
Striatal function in normal aging: Implications for Parkinson's disease (1990) (167)
Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases (1998) (167)
Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. (1997) (165)
Sexual function in patients with Parkinson's disease and their partners. (1990) (163)
Vestibular induced postural responses in Parkinson's disease. (1993) (162)
FETAL DOPAMINE-RICH MESENCEPHALIC GRAFTS IN PARKINSON'S DISEASE (1988) (162)
Influence of voluntary intent on the human long-latency stretch reflex (1980) (162)
Status dystonicus: the syndrome and its management (1998) (162)
Olfactory threshold in Parkinson's disease. (1987) (161)
The substituted benzamides--a novel class of dopamine antagonists. (1979) (161)
The rotating rodent: a two component system? (1978) (159)
Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy (1995) (159)
Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. (1992) (158)
Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. (1976) (157)
Time course of inhibition of brain nitric oxide synthase by 7-nitro indazole. (1994) (157)
Metoclopramide and dopamine receptor blockade (1976) (157)
A genetic study of idiopathic focal dystonias (1991) (156)
A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. (1998) (156)
The basal ganglia and apraxia. (1996) (155)
BASAL GANGLIA DISEASE (1982) (154)
Botulinum toxin treatment of spasmodic torticollis. (1988) (154)
Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. (1995) (154)
Simple and complex movements off and on treatment in patients with Parkinson's disease. (1987) (154)
The natural history of tardive dystonia. A long-term follow-up study of 107 cases. (1998) (153)
Accurate repositioning of the human thumb against unpredictable dynamic loads is dependent upon peripheral feed‐back (1982) (151)
The syndrome of painful legs and moving toes (1994) (151)
The interpretation of electromyographic responses to electrical stimulation of the motor cortex in diseases of the upper motor neurone (1987) (151)
ABNORMALITIES IN CENTRAL MOTOR PATHWAY CONDUCTION IN MULTIPLE SCLEROSIS (1984) (149)
A clinical and genetic study of familial Parkinson's disease (1991) (148)
Assessment of extrapyramidal disorders. (1981) (148)
Is the human stretch reflex cortical rather than spinal? (1973) (148)
Hysteria — a neurologist's view (1986) (148)
Mood swings associated with the ‘on—off’ phenomenon in Parkinson's disease (1987) (148)
Cognitive performance in multiple system atrophy. (1992) (147)
Simple and complex movements in a patient with infarction of the right supplementary motor area (1986) (147)
The myoclonus in corticobasal degeneration. Evidence for two forms of cortical reflex myoclonus. (1994) (147)
Serotonergic involvement with neuroleptic catalepsy (1975) (146)
Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography (1986) (144)
Changes in dopamine-mediated behaviour during one year's neuroleptic administration. (1979) (144)
Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. (1984) (144)
The performance on learning tasks of patients in the early stages of Parkinson's disease (1989) (143)
THE AMNESIC SYNDROME OF POSTERIOR CEREBRAL ARTERY OCCLUSION (1974) (143)
The stiff man and stiff man plus syndromes (1999) (142)
The nature of apraxia in corticobasal degeneration. (1994) (142)
Evidence favouring presynaptic inhibition between antagonist muscle afferents in the human forearm. (1987) (142)
Serotoninergic modulation of the dopamine response from the nucleus accumbens (1976) (139)
The role of D-1 and D-2 receptors (1980) (138)
Influence of vision on upper limb reaching movements in patients with cerebellar ataxia. (1998) (138)
Tremor associated with benign IgM paraproteinaemic neuropathy. (1996) (137)
The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-hydroxydopamine and electrolytic lesions of the ascending dopamine systems of rat brain (1976) (134)
Natural history of adult-onset idiopathic torticollis. (1990) (134)
Abnormalities of the balance between inhibition and excitation in the motor cortex of patients with cortical myoclonus. (1996) (133)
The role of DYT1 in primary torsion dystonia in Europe. (1998) (133)
Effect of digital nerve stimuli on responses to electrical or magnetic stimulation of the human brain. (1992) (132)
The treatment of severe dystonia in children and adults. (1984) (132)
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease (1991) (131)
COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPA (1982) (130)
Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine (1993) (130)
Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. (1980) (130)
Cortical outflow to proximal arm muscles in man. (1990) (130)
The effect of sleep on the dyskinetic movements of Parkinson's disease, Gilles de la Tourette syndrome, Huntington's disease, and torsion dystonia. (1991) (129)
Definition and classification of myoclonus. (1986) (129)
The use of peripheral feedback in the control of movement (1984) (128)
Substituted benzamides as cerebral dopamine antagonists in rodents (1977) (128)
Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease (1997) (127)
Motor reorganization in acquired hemidystonia (1995) (127)
Altered Muscarinic and Nicotinic Receptor Densities in Cortical and Subcortical Brain Regions in Parkinson's Disease (1993) (127)
Painful legs and moving toes. (1971) (127)
Substituted benzamide drugs as selective neuroleptic agents. (1981) (126)
Dopa‐responsive dystonia: A clinical and molecular genetic study (1998) (126)
Isolated single motor units in human muscle and their rate of discharge during maximal voluntary effort. (1971) (126)
Natural history of idiopathic torsion dystonia. (1976) (126)
Percutaneous electrical stimulation of lumbosacral roots in man. (1988) (126)
Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases (1999) (125)
Writer's cramp (1990) (124)
Muscle spasms associated with Sudeck's atrophy after injury. (1984) (123)
A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs (1978) (123)
Cabergoline in the treatment of early parkinson's disease (1997) (122)
The auditory startle response in the Steele-Richardson-Olszewski syndrome and Parkinson's disease. (1992) (122)
The physiology of orthostatic tremor. (1986) (122)
Striatal dopamine receptors become supersensitive while rats are given trifluoperazine for six months (1979) (122)
Pathophysiology of dystonias. (1983) (121)
Voluntary stimulus‐sensitive jerks and jumps mimicking myoclonus or pathological startle syndromes (1992) (120)
Further observations on the facilitation of muscle responses to cortical stimulation by voluntary contraction. (1991) (120)
The Bereitschaftspotential, L-DOPA and Parkinson's disease. (1987) (120)
Essential tremor: an overdiagnosed condition? (2000) (119)
Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period (1986) (118)
Early Treatment of Parkinson’s Disease with Cabergoline Delays the Onset of Motor Complications (1998) (118)
Intra-operative recording of motor tract potentials at the cervico-medullary junction following scalp electrical and magnetic stimulation of the motor cortex. (1991) (118)
Associated postural adjustments in Parkinson's disease. (1986) (117)
Neurological sequelae following carbon monoxide poisoning clinical course and outcome according to the clinical types and brain computed tomography scan findings (1994) (117)
Duration of the first agonist EMG burst in ballistic arm movements (1984) (116)
Dystonia in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy (1990) (115)
Automatic and ‘voluntary’ responses compensating for disturbances of human thumb movements (1982) (115)
Reliability and efficacy of the long‐latency stretch reflex in the human thumb. (1981) (114)
1-Methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway (1986) (114)
The enigma of the basal ganglia and movement (1980) (114)
A comparative study of simple and choice reaction time in Parkinson's, Huntington's and cerebellar disease. (1993) (114)
The effect of chronic neuroleptic administration on cerebral dopamine receptor function. (1983) (113)
The sensory mechanism of servo action in human muscle. (1977) (113)
Acute dystonia induced by neuroleptic drugs (2004) (113)
Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. (1998) (113)
Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. (1980) (112)
The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset (1985) (112)
Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. (1998) (111)
Propriospinal myoclonus: Evidence for spinal “pattern” generators in humans (1994) (111)
Letter: Bromocriptine in parkinsonism. (1975) (111)
The effect of adrenaline on the contraction of human muscle (1970) (111)
The clinical features and prognosis of chronic posthypoxic myoclonus (1997) (110)
Sequencing of the α-Synuclein Gene in a Large Series of Cases of Familial Parkinson's Disease Fails to Reveal any Further Mutations (1998) (110)
Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. (1996) (110)
Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease (1995) (110)
Circling behaviour produced by unilateral lesions in the region of the locus coeruleus in rats (1975) (109)
Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. (1984) (108)
On the significance of giant somatosensory evoked potentials in cortical myoclonus. (1984) (108)
The corticomotoneurone connection is normal in Parkinson's disease (1984) (108)
Observations on the reflex response to muscle vibration in man and its voluntary control. (1969) (108)
Cation regulation differentiates specific binding of [3 H]sulpiride and [3 H]spiperone to rat striatal preparations (1980) (108)
Menstrual‐related fluctuations in Parkinson's disease (1986) (107)
Mitochondrial DNA analysis in Parkinson's disease (1990) (107)
The relationship between trauma and idiopathic torsion dystonia. (1991) (107)
Postural responses to vibration of neck muscles in patients with idiopathic torticollis. (1997) (106)
The syndrome of gait ignition failure: A report of six cases (1993) (105)
Training improves the speed of aimed movements in Parkinson's disease. (1998) (104)
Bradykinesia and impairment of EEG desynchronization in Parkinson's disease (1999) (104)
Paroxysmal kinesigenic choreoathetosis: a report of 26 patients (1999) (103)
Increase of the Bereitschaftspotential in simultaneous and sequential movements (1985) (103)
Oxidative Stress and Parkinson's Disease a (1996) (103)
The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism. (1989) (102)
Abnormal motor unit synchronization of antagonist muscles underlies pathological co-contraction in upper limb dystonia. (1998) (102)
Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7‐nitro indazole (1995) (102)
Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. (1986) (101)
Trunk and head tremor as isolated manifestations of dystonia (1990) (101)
Note on the scoliosis of Parkinsonism. (1975) (100)
Hereditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion. (1988) (100)
Diaphragmatic flutter, the moving umbilicus syndrome, and “belly dancer's” dyskinesia (1990) (99)
Micturition disturbance in Parkinson's disease. (1985) (99)
Function of the Basal Ganglia as Revealed by Cognitive and Motor Disorders in Parkinson’s Disease (1984) (97)
Rotational behavior induced in rats by intranigral picrotoxin (1975) (97)
Effect of practice on performance of a skilled motor task in patients with Parkinson's disease. (1992) (97)
The problem of adult-onset idiopathic torsion dystonia and other isolated dyskinesias in adult life (including blepharospasm, oromandibular dystonia, dystonic writer's cramp, and torticollis, or axial dystonia). (1976) (97)
Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. (1980) (96)
A genetic study of idiopathic torsion dystonia in the United Kingdom. (1990) (96)
Does signal-attenuation on high-field T2-weighted MRI of the brain reflect regional cerebral iron deposition? Observations on the relationship between regional cerebral water proton T2 values and iron levels. (1989) (96)
The stiff leg syndrome. (1997) (96)
Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. (1985) (95)
Botulinum toxin in spasmodic torticollis. (1988) (95)
Paroxysmal exercise‐induced dystonia: Eight new sporadic cases and a review of the literature (1997) (94)
Dystonia: the spectrum of the disease. (1976) (94)
Altered 5‐HT metabolism with clonazepam, diazepam and diphenylhydantoin (1975) (94)
Dopa-responsive dystonia. (1994) (94)
Is nocturnal paroxysmal dystonia a form of frontal lobe epilepsy? (1992) (93)
Dystonia after head trauma (1994) (93)
Dopa‐responsive dystonia: [18F]dopa positron emission tomography (1991) (93)
Sex prevalence of focal dystonias. (1996) (92)
An investigation of the phenomenon of “set” in Parkinson's disease (1988) (91)
Rapid elbow movements in patients with torsion dystonia. (1989) (91)
Intrahemispheric and interhemispheric spread of cerebral cortical myoclonic activity and its relevance to epilepsy. (1991) (91)
Primary writing tremor. (1979) (89)
Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. (1976) (89)
Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. (1983) (88)
The execution of bimanual movements in patients with Parkinson's, Huntington's and cerebellar disease. (1993) (88)
Writer's cramp: Treatment with botulinum toxin injections (1991) (87)
Sequencing ability in Parkinsonians, patients with frontal lobe lesions and patients who have undergone unilateral temporal lobectomies (1989) (87)
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. (1986) (87)
Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls (1995) (87)
Transcranial electric and magnetic stimulation of the leg area of the human motor cortex: single motor unit and surface EMG responses in the tibialis anterior muscle. (1993) (87)
Dementia and Parkinson's disease--pathological and neurochemical considerations. (1986) (87)
EFFECT OF ADRENERGIC β-BLOCKADE ON PARKINSONIAN TREMOR (1965) (87)
The effect of lesions of the sensorimotor cortex and the capsular pathways on servo responses from the human long thumb flexor. (1977) (87)
Psychiatric symptoms during L-dopa therapy for Parkinson's disease and their relationship to physical disability (1976) (86)
The role of the ballistocardiac impulse in the genesis of physiological tremor. (1969) (86)
Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. (1993) (86)
Specific binding of [3H]sulpiride to rat striatal preparations (1979) (86)
An immunohistochemical study of the acute and long-term effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in the marmoset (1987) (86)
Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors. (1983) (85)
The blink reflex in patients with idiopathic torsion dystonia. (1990) (85)
Teaching tape for the motor section of the unified Parkinson's disease rating scale (1995) (84)
Movement disorders in multiple sclerosis (1995) (84)
The neuropathological features of neuroacanthocytosis (1994) (84)
Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease (1997) (83)
Habituation and conditioning of the human long latency stretch reflex (2004) (83)
Some experiences of techniques for stimulation of the human cerebral motor cortex through the scalp. (1987) (83)
The effect of posture on the normal and pathological auditory startle reflex. (1991) (83)
MANIPULATION OF BRAIN SEROTONIN IN THE TREATMENT OF MYOCLONUS (1975) (83)
Time course of postanoxic akinetic‐rigid and dystonic syndromes (1993) (82)
The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease. (1992) (82)
Disordered axial movement in Parkinson's disease. (1996) (82)
A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. (1984) (82)
Direct electrical stimulation of corticospinal pathways through the intact scalp in human subjects. (1983) (82)
Bromocriptine treatment in Parkinson's disease. (1976) (81)
Body concept, disability, and depression in patients with spasmodic torticollis. (1990) (81)
Some saccadic eye movements can be delayed by transcranial magnetic stimulation of the cerebral cortex in man. (1993) (81)
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. (1975) (80)
A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs. (1978) (79)
The causes of parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality (1998) (79)
Modulation of postural wrist tremors by magnetic stimulation of the motor cortex in patients with Parkinson's disease or essential tremor and in normal subjects mimicking tremor (1993) (79)
Correlation of phasic muscle strength and corticomotoneuron conduction time in multiple sclerosis (1991) (79)
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. (1997) (78)
The dystonias. (1990) (78)
Unilateral lesions of the globus pallidus: report of four patients presenting with focal or segmental dystonia (2000) (78)
L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. (1995) (78)
Depression in torticollis: a controlled study (1988) (78)
The α‐synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: A study of 230 European cases (1998) (78)
Learning manual pursuit tracking skills in patients with Parkinson's disease. (1997) (77)
The treatment of severe action myoclonus. (1989) (77)
GABA in Nervous System Function (1977) (77)
LEVODOPA TREATMENT MAY BENEFIT OR IMPAIR "FRONTAL" FUNCTION IN PARKINSON'S DISEASE (1986) (76)
NATURAL HISTORY, SYMPTOMS AND TREATMENT OF THE NARCOLEPTIC SYNDROME (1975) (76)
Abnormal access of axial vibrotactile input to deafferented somatosensory cortex in human upper limb amputees. (1997) (76)
The effect of posterior column lesions on servo responses from the human long thumb flexor. (1977) (76)
Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study. (1995) (75)
An exteroceptive reflex in the sternocleidomastoid muscle produced by electrical stimulation of the supraorbital nerve in normal subjects and patients with spasmodic torticollis (1989) (74)
Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study (1993) (74)
Familial paroxysmal dystonia induced by exercise. (1984) (74)
The significance of ophthalmological symptoms in idiopathic blepharospasm (1988) (74)
Response choice in Parkinson's disease. The effects of uncertainty and stimulus-response compatibility. (1993) (74)
Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. (1986) (74)
“Resetting” of postural tremors at the wrist with mechanical stretches in Parkinson's disease, essential tremor, and normal subjects mimicking tremor (1992) (74)
Effect of beta-adrenergic blockade on finger tremor and Achilles reflex time in anxious and thyrotoxic patients. (1968) (73)
Examination of motor function in lesions of the spinal cord by stimulation of the motor cortex (1987) (73)
Rapid wrist movements in patients with essential tremor. The critical role of the second agonist burst. (1994) (72)
Atypical and typical cranial dystonia following dental procedures (1999) (72)
Chronicl-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat (1995) (72)
Parkinson's disease in twins. (1987) (72)
The movement‐related cortical potential is abnormal in patients with idiopathic torsion dystonia (1995) (72)
A patient with reflex myoclonus and muscle rigidity: "jerking stiff-man syndrome". (1980) (71)
Effectiveness of piracetam in cortical myoclonus (1993) (71)
Primary orthostatic tremor: further observations in six cases (1992) (71)
α‐tocopherol levels in brain are not altered in Parkinson's disease (1992) (70)
PLASMA EXCHANGE AND IMMUNOSUPPRESSION IN THE STIFF MAN SYNDROME (1989) (70)
Kainic acid lesions of striatum and decortication reduce specific [3H]sulpiride binding in rats, so D‐2 receptors exist post‐synaptically on corticostriate afferents and striatal neurons (1981) (70)
The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors. (1986) (70)
Levodopa may improve orthostatic tremor: case report and trial of treatment (1999) (70)
Patients with Parkinson's disease can employ a predictive motor strategy. (1984) (69)
Mitochondrial respiratory chain function in multiple system atrophy (1997) (69)
Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of parkinson's disease patients (1994) (69)
Focal contralateral myoclonus produced by inhibition of GABA action in the caudate nucleus of rats. (1978) (68)
Evidence for locus heterogeneity in autosomal dominant torsion dystonia. (1993) (68)
Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration (1996) (67)
The behavioural effects of manipulating GABA function in the globus pallidus (1976) (67)
Variations in human physiological finger tremor, with particular reference to changes with age. (1969) (67)
Treatment of Parkinson's disease with amantadine and levodopa. A one-year study. (1971) (67)
The effect ofl-DOPA and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography (1991) (67)
beta-Adrenoreceptor antagonists in essential tremor. (1979) (67)
Problems with long-term levodopa therapy for Parkinson's disease. (1994) (67)
Dopa Dose-Dependent Sexual Deviation (1983) (67)
The roles of noradrenaline and dopamine in contraversive circling behaviour seen after unilateral electrolytic lesions of the locus coeruleus. (1976) (67)
Psychological functioning before and after treatment of torticollis with botulinum toxin. (1992) (66)
Familial parkinsonism with depression: A clinicopathological study (1993) (66)
Amphetamines in the treatment of Parkinson's disease. (1975) (66)
Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa. (1974) (66)
The relation between physiological tremor of the two hands in healthy subjects. (1969) (66)
Differential anatomical location of [3H]‐N,n‐propylnorapomorphine and [3 H]‐spiperone binding sites in the striatum and substantia nigra of the rat (1983) (66)
L‐Dopa Methyl Ester—A Candidate for Chronic Systemic Delivery of L‐Dopa in Parkinson's Disease (1984) (65)
Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. (1993) (65)
Chronic pharmacological manipulation of dopamine receptors in brain (1987) (65)
Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors. (1983) (65)
GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs (1997) (64)
Pathological report of four patients presenting with cranial dystonias (1988) (64)
Benign hereditary chorea—Entity or syndrome? (1999) (64)
Ramsay hunt syndrome and coeliac disease: A new association? (1986) (64)
COMPARISONS OF THERAPEUTIC EFFECTS OF LEVODOPA, LEVODOPA AND SELEGILINE, AND BROMOCRIPTINE IN PATIENTS WITH EARLY, MILD PARKINSONS-DISEASE - 3-YEAR INTERIM-REPORT (1993) (63)
Adrenoleukomyelo‐neuropathy presenting as spinocerebellar degeneration (1982) (63)
The motor disorder of multiple system atrophy. (1993) (63)
The effect of chronic l-DOPA treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts (1991) (63)
Movement‐related cortical potentials preceding repetitive and random‐choice hand movements in parkinson's disease (1995) (63)
Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP (1989) (63)
The Bereitschaftspotential preceding simple foot movement and initiation of gait in Parkinson's disease (1993) (63)
A Double‐Blind Trial of Clonazepam in Benign Essential Tremor (1984) (63)
Stereotaxic injection of kainic acid into the striatum of rats induces synthesis of mRNA for heat shock protein 70 (1988) (62)
Latency measurements compatible with a cortical pathway for the stretch reflex in man. (1973) (62)
A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. (1973) (62)
The corneal reflex and the R2 component of the blink reflex (1985) (62)
Pergolide in late‐stage Parkinson disease (1982) (62)
The Physiology of Idiopathic Dystonia (1987) (62)
Attitudes of families to some aspects of Huntington's chorea (1979) (62)
Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase (1998) (61)
Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment withl-DOPA and carbidopa (1992) (61)
Alien hand sign in association with Alzheimer's histopathology. (1993) (61)
Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. (1997) (60)
Beta-adrenoreceptor mechanisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol. (1983) (59)
Movement disorders in mitochondrial myopathies. A study of nine cases with two autopsy studies (1990) (59)
EXTRAPYRAMIDAL SIDE-EFFECTS OF METOCLOPRAMIDE (1978) (59)
Platelet mitochondria function in Parkinson's disease (1992) (59)
A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease (1994) (59)
Progressive myoclonic ataxia (the Ramsay Hunt syndrome). (1990) (59)
Effect of deafferentation on human physiological tremor. (1967) (59)
Transmission in the spinal reciprocal Ia inhibitory pathway preceding willed movements of the human wrist (1983) (59)
Focal task‐specific tremors (1996) (59)
TRAUMA AND PAIN IN SPASMODIC TORTICOLLIS (1980) (58)
Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease (1974) (58)
Neuromelanin and Parkinson's disease. (1983) (58)
Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (1995) (58)
Hemi-dystonia secondary to localised basal ganglia tumour. (1984) (58)
Prism adaptation and other tasks involving spatial abilities in patients with Parkinson's disease, patients with frontal lobe lesions and patients with unilateral temporal lobectomies (1990) (58)
Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs. (1989) (58)
Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1988) (58)
The neurophysiology of Tourette syndrome. (1982) (58)
Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease (1989) (57)
Do thermodynamic studies provide information on both the binding to and the activation of dopaminergic and other receptors? (1987) (57)
Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase (1973) (57)
The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. (1988) (57)
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy (1995) (57)
The timing of primary orthostatic tremor bursts has a task-specific plasticity. (2000) (57)
Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour. (1995) (56)
Sodium valproate in the treatment of levodopa-induced dyskinesia. (1978) (56)
Unusual focal dyskinesias: The ears, the shoulders, the back, and the abdomen (1994) (56)
The long-duration action of levodopa may be due to a postsynaptic effect. (1997) (56)
Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. (1994) (56)
Evidence that [3H]Dopamine Is Taken Up and Released from Nondopaminergic Nerve Terminals in the Rat Substantia Nigra In Vitro (1985) (56)
Pure akinesia due to lewy body Parkinson's disease: A case with pathology (1989) (56)
The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset (1988) (56)
Electrophysiological and positron emission studies in a patient with cortical myoclonus, epilepsia partialis continua and motor epilepsy. (1986) (55)
Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats (2004) (55)
L‐Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease ‡ (1987) (55)
Effect of angiotensin on renal function in the rat. (1967) (55)
Acanthocytosis, Retinitis Pigmentosa, and Pallidal Degeneration (1995) (55)
Comparison of the In‐vitro Receptor Selectivity of Substituted Benzamide Drugs for Brain Neurotransmitter Receptors (1988) (55)
Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. (1986) (54)
Chronic spinal muscular atrophy in adults (1969) (54)
Piracetam in the treatment of different types of myoclonus. (1988) (54)
Electrophysiological aids in distinguishing organic from psychogenic tremor (1998) (53)
Movements not involved in posture are abnormal in Parkinson's disease (1984) (53)
Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5‐hydroxytryptamine * (1975) (53)
Modulation of postural tremors at the wrist by supramaximal electrical median nerve shocks in essential tremor, Parkinson's disease and normal subjects mimicking tremor. (1993) (53)
Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. (1992) (53)
Writer's cramp. (1983) (53)
Cutaneous effects on presynaptic inhibition of flexor Ia afferents in the human forearm. (1990) (53)
Common 3 and 10 Hz oscillations modulate human eye and finger movements while they simultaneously track a visual target (1999) (52)
Lessons from a remarkable family with dopa-responsive dystonia. (1994) (52)
Ataxia without telangiectasia masquerading as benign hereditary chorea (1996) (52)
Relationship between plasma propranolol concentration and relief of essential tremor. (1979) (52)
Cerebral potentials and electromyographic responses evoked by stretch of wrist muscles in man (2004) (51)
Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats (1991) (51)
Clonazepam induces decreased serotoninergic activity in the mouse brain (1979) (51)
Relationship between animal models and clinical parkinsonism. (1975) (51)
Comparison of striatal 18F‐dopa uptake in adult‐onset dystonia‐parkinsonism, Parkinson's disease, and dopa‐responsive dystonia (1993) (51)
Mutation analysis in patients with possible but apparently sporadic Huntington's disease (1994) (51)
Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias. (1978) (51)
Cortical myoclonus in huntington's disease (1994) (51)
Writing tremor: its relationship to benign essential tremor. (1985) (51)
EMG biofeedback treatment of torticollis: A controlled outcome study (1991) (50)
The neck-tongue syndrome. (1994) (50)
Vestibulo-ocular abnormalities in spasmodic torticollis before and after botulinum toxin injections. (1989) (50)
Clinical and pathological features of corticobasal degeneration. (1990) (50)
Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats (2004) (50)
Postanoxic symptomatic oscillatory myoclonus (1983) (50)
Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. (1989) (50)
D3 receptor expression within the basal ganglia is not affected by Parkinson's disease (1996) (50)
Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. (1996) (50)
Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP‐treated common marmoset (1996) (50)
Effects of opioid agonist drugs on the in vitro release of 3H-GABA, 3H-dopamine and 3H-5HT from slices of rat globus pallidus. (1987) (49)
Nigral dopaminergic cell loss in vitamin E deficient rats. (1994) (49)
Ipsilateral blepharospasm and contralateral hemidystonia and parkinsonism in a patient with a unilateral rostral brainstem– thalamic lesion: Structural and functional abnormalities studied with CT, MRI, and PET scanning (1986) (49)
Investigation of dystonia. (1988) (49)
Stereotactic thalamotomy in tremor‐dominant Parkinson's disease: An H215O PET motor activation study (1997) (49)
Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. (1994) (49)
The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. (1993) (49)
Are dopamine receptors present on human lymphocytes? (1982) (48)
Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data. (1986) (48)
Botulinum toxin antibody testing: Comparison between the mouse protection assay and the mouse lethality assay (2000) (48)
Hereditary geniospasm: linkage to chromosome 9q13-q21 and evidence for genetic heterogeneity. (1997) (48)
Spastic dysphonia, Meige disease, and torsion dystonia (1982) (48)
L-dopa and frontal cognitive function in Parkinson's disease. (1993) (48)
Complex stereotypies after right putaminal infarction: A case report (1991) (47)
Electrophysiology of the corticomotoneurone pathways in patients with movement disorders (1986) (47)
Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD). (1998) (47)
Lisuride in parkinsonism (1981) (47)
Corticobasal degeneration. (1989) (47)
Effect of Experimental Ischemia on Neurotransmitter Amines in the Gerbil Brain (1979) (47)
Central motor conduction time in progressive multiple sclerosis. Correlations with MRI and disease activity. (1998) (47)
Pigmentation in the nucleus substantiae nigrae of mammals. (1961) (46)
Comparison of the effects of benzodiazepines and other anticonvulsant drugs on synthesis and utilization of 5-ht in mouse brain (1985) (46)
A distal form of chronic spinal muscular atrophy (1969) (46)
Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration (2005) (45)
Primary writing tremor. (1979) (45)
Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum (1982) (45)
Familial dystonia and visual failure with striatal CT lucencies. (1986) (45)
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets (1999) (45)
A case‐control study of idiopathic torsion dystonia (1991) (45)
PHYSIOLOGICAL-STUDIES IN A PATIENT WITH MIRROR MOVEMENTS AND AGENESIS OF THE CORPUS-CALLOSUM (1991) (44)
Striatal neuropeptide levels in Parkinson's disease patients (1992) (44)
A grab reflex in the human hand. (1980) (44)
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin (1989) (44)
Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. (1989) (44)
Striatal [18F]dopa uptake in familial idiopathic dystonia. (1993) (43)
Successful treatment of stiff man syndrome with intravenous immunoglobulin. (1997) (43)
L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain (1995) (43)
Turning behaviour induced by injection of muscimol or picrotoxin into the substantia nigra demonstrates dual GABA components (1979) (43)
Rhythmic cortical and muscle discharge in cortical myoclonus. (1996) (42)
Neuroleptic‐induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors (1981) (42)
Does an endogenous methylpyridinium analogue cause Parkinson's disease? (1985) (42)
Perception of spatial orientation in spasmodic torticollis part I: The postural vertical (1997) (42)
Botulinum toxin in the treatment of writer's cramp. (1996) (42)
DIFFERENCES BETWEEN ELECTRICAL AND MAGNETIC STIMULATION OF THE HUMAN-BRAIN (1986) (42)
Acute dystonia as an idiosyncratic response to neuroleptics in baboons. (1977) (42)
Nigrostriatal function in vitamin E deficiency: Clinical, experimental, and positron emission tomographic studies (1994) (41)
Clinical features and natural history of axial predominant adult onset primary dystonia (1997) (41)
Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity (1976) (41)
A functional assessment of embryonic dopaminergic grafts in the marmoset. (1990) (41)
Growth hormone response to clonidine in central and peripheral primary autonomic failure (1992) (41)
Wilson's disease. (1987) (41)
Pain and remote weakness in limbs injected with botulinum toxin A for writer's cramp (1995) (41)
ERRATA : DIRECTION OF CURRENT IN MAGNETIC STIMULATING COILS USED FOR PERCUTANEOUS ACTIVATION OF BRAIN, SPINAL CORD AND PERIPHERAL NERVE (1990) (41)
The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or α-methyl-p-tyrosine pre-treated mice (1976) (41)
Nigral degeneration in neuroacanthocytosis (1994) (41)
Effects of motor cortex stimulation on spinal interneurones in intact man (2004) (41)
Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and l-DOPA treatment (1996) (40)
Levels of MET-enkephalin, LEU-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment (1988) (40)
Corticobasal degeneration. (1992) (40)
Severe generalised dystonia associated with a mosaic pattern of striatal gliosis (1992) (40)
Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat. (1996) (40)
Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations (2004) (40)
A case of postanoxic encephalopathy with cortical action and brainstem reticular reflex myoclonus (1991) (40)
Electrophysiology of somatosensory reflex myoclonus. (1986) (40)
Central dopaminergic receptor supersensitivity and its relevance to Parkinson's disease (1977) (40)
Alpha methylparatyrosine and tetrabenazine in movement disorders. (1982) (39)
SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors. (1985) (39)
The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset (1986) (39)
Mechanisms underlying emotional variation in parkinsonian tremor (1967) (39)
The functions of the supplementary motor area. Summary of a workshop. (1996) (39)
A genetic study of torsion dystonia. (1975) (39)
Do enkephalins in basal ganglia mediate a physiological motor rest mechanism? (1986) (39)
Parkinson's Disease, Cerebral Arteriosclerosis, and Senile Dementia (1974) (39)
Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets (1997) (39)
Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera (1996) (38)
A Longitudinal Follow-up Study of Depression, Disability, and Body Concept in Torticollis. (1990) (38)
The isomers of thioctic acid alter C-deoxyglucose incorporation in rat basal ganglia. (1996) (38)
LISURIDE IN PARKINSON'S DISEASE (1979) (37)
Progressive frontal gait disturbance with atypical Alzheimer’s disease and corticobasal degeneration (1999) (37)
Is tardive dyskinesia a unique disorder? (1985) (37)
Stereoselective actions of substituted benzamide drugs on cerebral dopamine mechanisms (1980) (37)
CEREBRAL ATROPHY AND COGNITIVE IMPAIR MENT IN CHRONIC SCHIZOPHRENIA (1976) (37)
Tyrosine hydroxylase polymorphism in familial and sporadic Parkinson's disease (1994) (37)
Altered Motor Function and Graft Survival Produced by Basic Fibroblast Growth Factor in Rats with 6-OHDA Lesions and Fetal Ventral Mesencephalic Grafts Are Associated with Glial Proliferation (1996) (37)
The effect of carbidopa on plasma and muscle levels of L‐dopa, dopamine, and their metabolites following L‐dopa administration to rats (1988) (36)
Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity (1988) (36)
Multiple-system atrophy is genetically distinct from identified inherited causes of spinocerebellar degeneration (1997) (36)
The effect of manipulation of cholinergic mechanisms on turning behaviour in mice with unilateral destruction of the nigro-neostriatal dopaminergic system (1978) (36)
Detailed genotyping demonstrates association between the slow acetylator genotype for N‐Acetyltransferase 2 (NAT2) and familial parkinson's disease (2000) (36)
Personality in torticollis: a controlled study (1988) (36)
Paroxysmal dystonic choreoathetosis. Genetic linkage studies in a British family. (1997) (36)
Paroxysmal dystonic head tremor (1991) (36)
Motor inhibition from the brainstem is normal in torsion dystonia during REM sleep. (1991) (36)
Clinical neurophysiology of muscle jerks: myoclonus, chorea, and tics. (1983) (36)
Degenerative cerebellar ataxia and focal dystonia (1988) (36)
Human anticipatory eye movements may reflect rhythmic central nervous activity (1999) (36)
Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. (1996) (36)
An appraisal of the antiparkinsonian activity of piribedil in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets (1996) (36)
5-Hydroxytryptophan-induced myoclonus in guinea pigs A physiological and pharmacological investigation (1978) (35)
Role of noradrenaline in levodopa reversal of reserpine akinesia. (1974) (35)
The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety (1985) (35)
Cardiovascular and hormonal responses to liquid food challenge in idiopathic Parkinson's disease, multiple system atrophy, and pure autonomic failure (1993) (35)
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset (1995) (35)
Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. (1996) (35)
Servo action and stretch reflex in human muscle and its apparent dependence on peripheral sensation. (1971) (35)
Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism. (1982) (35)
Nomifensine in Parkinson's disease. (1977) (34)
Dopamine and basal ganglia disorders in humans (1992) (34)
Motor disorders in schizophrenia (1982) (34)
Botulinum toxin treatment of spasmodic torticollis. (1992) (34)
Nitric oxide synthase mRNA expression in human subthalamic nucleus, striatum and globus pallidus: implications for basal ganglia function. (1994) (33)
Linkage analysis in British and French families with idiopathic torsion dystonia. (1993) (33)
Multiple Dopamine Receptors in Brain and the Pharmacological Action of Substituted Benzamide Drugs (1984) (33)
A familial disorder associated with palatal myoclonus, other brainstem signs, tetraparesis, ataxia and Rosenthal fibre formation. (1993) (33)
Dystonia as the major manifestation of Leigh's syndrome (1994) (33)
Paroxysmal axial spasms of spinal origin (1991) (33)
Focal myoclonus produced by injection of picrotoxin into the caudate nucleus of the rat. (1975) (33)
Pharmacological analysis of the myoclonus induced by 5-hydroxytryptophan in the guinea pig suggests the presence of multiple 5-hydroxytryptamine receptors in the brain (1981) (33)
The Bereitschaftspotential preceding stepping in patients with isolated gait ignition failure (1995) (32)
Effect of thumb anaesthesia on weight perception, muscle activity and the stretch reflex in man. (1979) (32)
Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers. (1987) (32)
Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the dopamine D3 receptor antagonist GR103691 with typical and atypical neuroleptics. (1996) (32)
Ballistic movement overflow myoclonus a form of essential myoclonus. (1977) (32)
Movement disorders and the basal ganglia (1986) (32)
The pathophysiology of movement disorders. (1984) (32)
Potent lipophilic substituted benzamide drugs are not selective D‐1 dopamine receptor antagonists in the rat (1983) (32)
PERFORMANCE OF VARIOUS TYPES OF SIMULTANEOUS MOVEMENTS IN PATIENTS WITH PARKINSONS-DISEASE (1985) (32)
Anticipatory postural responses in the human subject [proceedings]. (1978) (31)
Lack of Change in Basal Ganglia Neuropeptide Content Following Subacute 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Treatment of the Common Marmoset (1986) (31)
Chronic spinal muscular atrophy in adults. 2. Other forms. (1969) (31)
The involvement of noradrenaline in motor activity as shown by rotational behaviour after unilateral lesions of the locus coeruleus. (1976) (31)
Viewpoints on the Ramsay Hunt syndrome. The Ramsay Hunt syndrome is a useful clinical entity (1989) (31)
Rapid postural reactions to mechanical displacement of the hand in man. (1983) (31)
Differential labelling of dopamine receptors in rat brain in vivo: comparison of [3H]piribedil, [3H]S 3608 and [3H]N,n-propylnorapomorphine. (1983) (31)
The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: An in situ hybridization study (1999) (31)
L-5-HYDROXYTRYPTOPHAN AND MOOD (1975) (31)
Hereditary geniospasm: Two new families (1996) (30)
The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson's Disease. (1998) (30)
The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents (1977) (30)
FUNCTIONAL CHANGES IN CEREBRAL 5‐HYDROXYTRYPTAMINE METABOLISM IN THE MOUSE INDUCED BY ANTICONVULSANT DRUGS (1978) (30)
Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man (1990) (30)
The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease (1995) (30)
Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease (1973) (30)
Reciprocal inhibition between muscles of the human forearm in normal subjects and in patients with idiopathic torsion dystonia. (1988) (30)
Modulation of the long-latency reflex to stretch by the supplementary motor area in humans (1987) (30)
Cerebellar axial postural tremor (1997) (30)
in vitro characterisation of dopamine receptors in the superior colliculus of the rat (1987) (30)
WHEN SHOULD LEVODOPA BE STARTED? (1986) (30)
Failure of lithium treatment in established tardive dyskinesia (1980) (30)
Characterization of neurotensin-like immunoreactivity in human basal ganglia: Increased neurotensin levels in substantia nigra in Parkinson's disease (1995) (30)
Rotational behaviour produced in rats by unilateral electrolytic lesions of the ascending noradrenergic bundles (1977) (30)
Atypical presentations of dopa-responsive dystonia. (1998) (29)
Localization of neurotensin receptors in the forebrain of the common marmoset and the effects of treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1987) (29)
Myoclonic dystonia (1983) (29)
Parkinson's disease. (1994) (29)
Unilateral pallidotomy for Parkinson’s disease: results after more than 1 year (1999) (29)
Brain dopaminergic system studied in patients with dystonia using positron emission tomography. (1988) (29)
Vestibular, cervical and visual remembered saccades in Parkinson's disease. (1994) (29)
Expression and localisation of CYP2D enzymes in rat basal ganglia (1999) (29)
Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity. (1982) (29)
Nitric oxide synthase inhibition and MPTP‐induced toxicity in the common marmoset (1997) (29)
The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice antagonism by monoamine oxidase inhibitors Antagonism by monoamine oxidase inhibitors (1986) (29)
Specific [3H]Piflutixol Binding to CHAPS‐Solubilised Rat Striatal Preparations Involves Dopamine D‐2 but Not D‐1 Binding Sites (1986) (29)
Primary central nervous system lymphoma presenting with a parkinsonian syndrome of pure akinesia (1999) (29)
Problems in Parkinson's disease (1981) (29)
Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1996) (29)
Linkage analysis with chromosome 9 markers in hereditary essential tremor (1993) (29)
Behavioural effects in rats of unilateral and bilateral injections of opiate receptor agonists into the globus pallidus (1985) (29)
Alcohol and Parkinson disease (1982) (29)
Paroxysmal dystonic choreoathetosis: Clinical features and investigation of pathophysiology in a large family (2000) (28)
Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy (2000) (28)
Leukocyte glutamate dehydrogenase activity in patients with degenerative neurological disorders. (1988) (28)
Classification of extrapyramidal disorders. Proposal for an international classification and glossary of terms. (1981) (28)
Debrisoquine hydroxylation in Parkinson's disease (1992) (28)
Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats. (1985) (28)
Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (1995) (28)
Dystonia induced by combined treatment with L‐dopa and MK‐801 in parkinsonian monkeys (1992) (28)
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study (1994) (28)
BEHAVIOURAL CHANGES INDUCED BY N,N‐DIMETHYLTRYPTAMINE IN RODENTS (1980) (28)
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. (1995) (28)
MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects. (1987) (28)
The focal dystonias. (1986) (28)
Interaction of neuroleptic drugs with rat striatal D-1 and D-2 dopamine receptors: a quantitative structure—affinity relationship study (1988) (28)
BETA-ADRENOCEPTOR ANTAGONISTS AND ESSENTIAL TREMOR (1981) (28)
The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results (1989) (27)
Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group. (1992) (27)
5-Hydroxytryptamine (5-HT)-dependent myoclonus in guinea pigs is induced through brainstem 5-HT-1 receptors (1984) (27)
Interruption of motor programmes by electrical or magnetic brain stimulation in man. (1989) (27)
The effect of nitric oxide synthase inhibition on quinolinic acid toxicity in the rat striatum (1995) (27)
Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism. (1978) (27)
Morphologic studies on adult neuronal-ceroid lipofuscinosis (NCL). (1982) (27)
Primate models of neurological disorders (1975) (27)
Pilocarpine-induced purposeless chewing behaviour in rats is dependent on intact central stores of 5-HT. (1987) (27)
Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [Met5]- and [Leu5]-enkephalin and neurotensin content in the rat. (1991) (27)
Motor disturbances 1 (1987) (27)
Anticholinergic‐induced chorea in the treatment of focal dystonia (1987) (27)
Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D2 and D3 receptors in rat brain (1996) (27)
Dystonia of the legs induced by walking or passive movement of the big toe in a patient with cerebellar ectopia and syringomyelia (1986) (26)
The mode of action of sulpiride as an atypical antidepressant agent. (1982) (26)
Letter: Growth-hormone responses in Parkinson's disease. (1976) (26)
Perception of spatial orientation in spasmodic torticollis. Part 2: The visual vertical (1997) (26)
Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment. (1981) (26)
Somatosensory evoked potentials in myoclonus. (1986) (26)
Is the dopamine hypothesis of tardive dyskinesia completely wrong? (1986) (26)
Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat (2004) (26)
Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways. (1983) (26)
BROMOCRIPTINE IN PARKINSONISM (1975) (26)
Successful treatment of childhood onset symptomatic dystonia with levodopa. (1993) (26)
Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset. (1986) (26)
L-dopa's action in parkinson's disease (1981) (26)
PROCEDURAL MEMORY AND NEUROLOGICAL DISEASE (1992) (25)
Lisuride in dystonia (1985) (25)
Circling behaviour produced by asymmetric medial raphe nuclei lesions in rats (1976) (25)
Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake. (1983) (25)
"Isolated" postinfectious myoclonus. (1992) (25)
TIAPRIDE IN PARKINSON'S DISEASE (1978) (25)
Sequence of the superoxide dismutase 1 (SOD 1) gene in familial Parkinson's disease. (1995) (25)
Corticobasal degeneration look-alikes. (2000) (25)
[3H]SCH 23390 identifies D‐1 binding sites in rat striatum and other brain areas (1986) (25)
Posteroventral pallidotomy can ameliorate attacks of paroxysmal dystonia induced by exercise (1998) (25)
L‐Arginine produces NO‐independent increases in dopamine efflux in rat striatum (1998) (25)
Overdiagnosis of essential tremor (1999) (25)
BRAIN MUSCARINIC RECEPTORS IN ALZHEIMER'S AND PARKINSON'S DISEASES (1989) (25)
Myopathy associated with anticonvulsant osteomalacia. (1973) (25)
Scoliosis and Parkinson's disease. (1980) (25)
Cation specificity of 3H-sulpiride binding involves alteration in the number of striatal binding sites. (1983) (25)
The GTP-cyclohydrolase I gene in atypical Parkinsonian patients: a clinico-genetic study (1996) (25)
Plasma DOPA levels and growth hormone response to levodopa in parkinsomism. (1977) (24)
Multiple sclerosis presenting as adult onset dystonia (1988) (24)
Differential alterations in striatal acetylcholine function in rats during 12 months' continuous administration of haloperidol, sulpiride, or clozapine. (1986) (24)
The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism. (1974) (24)
Brain muscarinic cholinergic receptors in Huntington's disease (1992) (24)
Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats. (1986) (24)
Antiparkinsonian activity of (+)‐PHNO in the MPTP‐treated common marmoset (1987) (24)
Opiate antagonists and Parkinson's disease. (1979) (24)
Long latency stretch reflex of the human thumb can be reversed if the task is changed [proceedings]. (1979) (24)
What do the basal ganglia tell premotor cortical areas? (1987) (24)
Sleep spindles in torsion dystonia. (1990) (24)
Analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as monoamine oxidase substrates: a second ring is not necessary (1987) (24)
Receptor changes during chronic dopaminergic stimulation. (1988) (23)
Dopa‐responsive dystonia (1994) (23)
Tryptamine-induced myoclonus in guinea-pigs pretreated with a monoamine oxidase inhibitor indicates pre- and post-synaptic actions of tryptamine upon central indoleamine systems (1982) (23)
Pharmacology of cranial dystonia (1983) (23)
Effect of adrenergic beta-blockade on parkinsonian tremor. (1966) (23)
MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal area (1986) (23)
Levodopa reversible loss of the Piper frequency oscillation component in Parkinson's disease (2001) (23)
Acute anticholinergic action in focal dystonia. (1983) (23)
Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. (1987) (23)
The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat (2006) (23)
The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (1989) (23)
The effects of dopamine and dopamine agonists on the release of 3H-GABA and 3H-5HT from rat nigral slices. (1985) (23)
LITHIUM FOR PAINFUL DYSTONIA IN PARKINSON'S DISEASE (1986) (23)
Behavior of the long-latency stretch reflex prior to voluntary movement (1981) (22)
The effect of diphenylhydantoin on central catecholamine containing neuronal systems (1977) (22)
Tyrosine hydroxylase and levodopa responsive dystonia. (1989) (22)
[Functions of the basal ganglia]. (1982) (22)
Interaction between the long-latency stretch reflex and voluntary electromyographic activity prior to a rapid voluntary motor reaction (1983) (22)
Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations. (1987) (22)
Glutamate decarboxylase-67 messenger RNA expression in normal human basal ganglia and in Parkinson's disease (1996) (22)
Metabolite involvement in bromocriptine‐induced circling behaviour in rodents (1980) (22)
Neuronal filaments in Alzheimer's, Pick's, and Parkinson's diseases. (1985) (22)
A movement disorder as a presenting feature of recurrent hypoglycaemia (1990) (22)
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets (2005) (22)
Idiopathic blepharospasm does not lead to a parkinsonian syndrome: results of a questionnaire-based follow-up study (1999) (22)
Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets (1999) (22)
The pathophysiology of cranial dystonia. (1988) (21)
Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP (1991) (21)
MOTOR CORTEX EXCITABILITY IN FOCAL AND GENERALIZED EPILEPSY (1993) (21)
Frontiers in neuroendocrinology 1969 (1971) (21)
Behavioural and morphological changes following treatment with GM-1 ganglioside of rats with an electrolytic lesion of the substantia nigra (1989) (21)
An experimental model of tardive dyskinesias. (1978) (21)
An unusual jaw tremor with characteristics of primary orthostatic tremor (1999) (21)
Physiology of negative myoclonus. (1995) (21)
Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of l-DOPA to rats (1984) (21)
Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. (1996) (21)
Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats (2004) (21)
Comparison of HPLC and Enzymatic Recycling Assays for the Measurement of Oxidized Glutathione in Rat Brain (1997) (21)
The clinical use of apomorphine in Parkinson's disease (1992) (21)
Contraversive circling behaviour produced by unilateral electrolytic lesions of the ventral noradrenergic bundle mimicking the changes seen with unilateral electrolytic lesions of the locus coeruleus (1976) (21)
Contact with a nurse practitioner: a short-term evaluation study in Parkinson's disease and dystonia. (1994) (21)
New Inventions: OBJECTIVE MEASUREMENT OF PARKINSONIAN TREMOR (1965) (21)
Facial dystonia in pathologically proven multiple system atrophy: A video report (1996) (20)
MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE (1992) (20)
The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. (1987) (20)
GABAergic modulation of striatal peptide expression in rats and the alterations induced by dopamine antagonist treatment (1994) (20)
RELIEF OF ACTION MYOCLONUS BY 5-HYDROXYTRYPTOPHAN (1974) (20)
A follow‐up study of isolated cases of suspected Huntington's disease (1992) (20)
IS MOLLARET'S MENINGITIS ANOTHER PERIODIC DISORDER RESPONSIVE TO COLCHICINE ? (1975) (20)
Serotonergic sprouting in the neostriatum after intrastriatal transplantation of fetal ventral mesencephalon (1991) (20)
Myoclonus in guniea pigs is induced by indole-containing but not piperazine-containing 5HT agonists. (1982) (20)
Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation (2005) (20)
Unilateral abolition of extrapyramidal rigidity after ipsilateral cerebellar, infarction (1987) (20)
Writer's cramp. (1983) (19)
The Clinical Efficacy of Oral Levodopa Methyl Ester Solution in Reversing Afternoon “Off” Periods in Parkinson's Disease (1991) (19)
Motor function in a patient with bilateral lesions of the globus pallidus (1995) (19)
Contractures of the extremities in parkinsonian subjects: a report of three cases with a possible association with bromocriptine treatment. (1988) (19)
PERIPHERAL AND CENTRAL MECHANISMS OF RECIPROCAL INHIBITION IN THE HUMAN FOREARM (1981) (19)
The role of nigral projections to the thalamus in drug-induced circling behaviour in the rat. (1981) (19)
Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats (1984) (19)
Intravenous boluses and continuous infusions of L‐DOPA methyl ester in fluctuating patients with Parkinson's disease (1992) (19)
Exercise induced steroid dependent dystonia, ataxia, and alternating hemiplegia associated with epilepsy (1998) (19)
Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain. (1981) (19)
A comparison of motor behaviours in groups of rats distinguished by their climbing response to apomorphine (1986) (19)
l‐Dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice ‡ (1987) (19)
Mitochondrial DNA polymorphisms in pathologically proven Parkinson’s disease (1997) (19)
Assessment of the muscarinic receptor subtype involved in the mediation of pilocarpine-induced purposeless chewing behaviour (2004) (18)
Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation. (1992) (18)
Sleep benefit in Parkinson’s disease (1999) (18)
Motor disorders in basal ganglia disease. (1984) (18)
TARDIVE DYSTONIA AND INAPPROPRIATE USE OF NEUROLEPTIC DRUGS (1982) (18)
Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset (1985) (18)
Writer's cramp: Not associated with anxiety (1988) (18)
The effect of adrenaline on the response to muscle vibration in man. (1969) (18)
Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients (1993) (18)
Peripheral Pharmacokinetic Handling and Metabolism of L‐Dopa in the Rat: The Effect of Route of Administration and Carbidopa Pretreatment (1991) (18)
Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents (2004) (17)
Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity (2005) (17)
Specific receptors for substituted benzamide drugs in brain. (1982) (17)
Corticospinal function in conversion disorder. (1997) (17)
Selective increase in somatostatin mRNA expression in human basal ganglia in Parkinson's disease. (1997) (17)
Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal. (1980) (17)
SSRI‐induced reversal of levodopa benefit in two patients with dopa‐responsive dystonia (1999) (17)
L-DOPA esters as potential prodrugs. I: Physicochemical properties (1985) (17)
Neurobehavioural changes in a patient with bilateral lesions of the globus pallidus. (1993) (17)
Off‐period screaming accompanying motor fluctuations in Parkinson's disease (1991) (17)
Noradrenaline-sensitive adenylate cyclase in slices of mouse limbic forebrain: characterisation and effect of dopaminergic agonists. (1977) (16)
Reversible supranuclear ophthalmoplegia associated with Parkinsonism. (1980) (16)
Estrogens and dyskinesia (1984) (16)
Drug treatment of diseases characterized by abnormal movements. (1973) (16)
Treatment of nonoccupational limb and trunk dystonia with botulinum toxin (1996) (16)
Functions of the Mammalian Carotid Rete Mirabile (1961) (16)
Cortical Reflex Myoclonus Responds to Intravenous Lisuride (1983) (16)
Drug-induced circling after unilateral 6-hydroxydopamine lesions of the nigro-striatal pathway is mediated via the midbrain periaqueductal grey and adjacent reticular formation (angular complex). (1981) (16)
Motor strategies involved in the performance of sequential movements (2004) (16)
AN INVESTIGATION OF THE EMG SILENT PERIOD FOLLOWING STIMULATION OF THE BRAIN IN NORMAL MAN (1989) (16)
Continuous subcutaneous lisuride infusions in Parkinson's disease. (1988) (16)
The effect of adrenaline on the contraction of human muscle--one mechanism whereby adrenaline increases the amplitude of physiological tremor. (1968) (16)
Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivity. (1983) (15)
(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE IN PARKINSON'S DISEASE (1986) (15)
Status dystonicus: the syndrome and its management. (1998) (15)
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. (1992) (15)
Alterations in brain 5HT and tryptamine content during indoleamine-induced myoclonus in guinea pigs. (1983) (15)
Continuous dopaminergic stimulation: state of the art and outlook. (1988) (15)
Exacerbation of postural tremor with emergence of parkinsonism after treatment with neuroleptic drugs. (1995) (15)
Effect of 7‐nitro indazole on quinolinic acid‐induced striatal toxicity in the rat (1995) (15)
Adaptive changes in brain dopamine function as a result of neuroleptic treatment. (1988) (15)
The Shy-Drager syndrome. What did Shy and Drager really describe? (1995) (15)
Alpha-tocopherol levels in brain are not altered in Parkinson's disease. (1992) (15)
GENETIC-HETEROGENEITY IN AUTOSOMAL-DOMINANT NOCTURNAL FRONTAL-LOBE EPILEPSY (1995) (15)
Differential effect of cutanoeous stimuli on responses to electrical or magnetic stimulation of the humain brain (1988) (15)
Glutamatergic regulation of striatal peptide gene expression in rats (1995) (15)
Cortical nicotinic receptors in Alzheimer's disease and Parkinson's disease. (1991) (14)
Reversal of reserpine-induced bradykinesia by alpha-methyldopa--new light on its modus operandi. (1974) (14)
Concentrations of GABA and Other Amino Acids in CSF from Torsion Dystonia Patients (1982) (14)
Vascular chorea: Case report with pathology (1994) (14)
Administration of MPTP to the common marmoset does not alter cortical cholinergic function (1986) (14)
Servo Control, the Stretch Reflex and Movement in Man (1973) (14)
Antiparkinsonian activity of single oral dose of PHNO (1987) (14)
The auditory startle response in progressive supranuclear palsy. (1994) (14)
Properties of rat striatal D‐2 dopamine receptors solubilized with the zwitterionic detergent CHAPS (1985) (14)
Circling behavior following unilateral kainic acid injections into rat striatum. (1981) (14)
Changes in loop gain with force in the human muscle servo. (1972) (14)
NEAR-PURE XYLENE CAUSING REVERSIBLE NEUROPSYCHIATRIC DISTURBANCE (1988) (14)
Proceedings: The effect of lesions in the internal capsule and the sensorimotor cortex on servo action in the human thumb. (1976) (14)
Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-DOPA and carbidopa (2005) (14)
Saccadic function in spasmodic torticollis. (1990) (14)
Pharmacological characterization of binding sites identified in rat brain following in vivo administration of [3H]‐spiperone. (1987) (13)
Coincidence of Wilson's disease with other movement disorders in the same family. (1986) (13)
Acute and repeated administration of sulpiride alters Met- and Leu-enkephalin content of rat brain (1986) (13)
Stretch reflex blepharospasm (1985) (13)
Lesions of the globus pallidus, entopeduncular nucleus and substantia nigra alter dopamine mediated circling behaviour (2004) (13)
Drug Interactions and Their Mechanisms (1977) (13)
Behaviour of short and long latency components of the stretch reflex in human muscle. (1975) (13)
Transplanted allogeneic fetal dopamine neurons survive and improve motor function in idiopathic Parkinson's disease. (1991) (13)
Progressive Intellectual Deterioration (1977) (13)
A comparison of the effects of acute and one year's continuous neuroleptic treatment on the release of [3H]glutamate and [3H]acetylcholine from rat striatal slices (1984) (13)
Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats (1987) (13)
During one year's neuroleptic treatment in rats striatal dopamine receptor blockade decreases but serum prolactin levels remain elevated. (1981) (13)
Basicity, Lipophilicity, and Lack of Receptor Interaction of N‐Aminoalkylbenzamides and N‐Aminoalkyl‐o‐anisamides as Model Compounds of Dopamine Antagonists (1983) (13)
Central motor conduction in neurological disease (1985) (13)
Orofacial dystonia and rest tremor in a patient with normal brain pathology (1993) (13)
Urea-induced stimulus-sensitive myoclonus in the rat. (1986) (12)
Pathology of MPTP in the marmoset. (1987) (12)
Magnetic stimulation of the human brain can activate different neuronal elements when the magnetic field direction is reversed (1988) (12)
Treatment of posthypoxic action myoclonus: implications for the pathophysiology of the disorder. (1986) (12)
Effect of speed of muscle contraction on physiological tremor in normal subjects and in patients with thyrotoxicosis and myxoedema1 (1970) (12)
Chronic spinal muscular atrophy in adults. 1. The Kugelberg-Welander syndrome. (1969) (12)
A therapeutic trial of milacemide in myoclonus and the stiff‐person syndrome (1991) (12)
The effect of long-term treatment with amine-depleting drugs or chlorpromazine on α-adrenoreceptors and 5-HT2 receptors in the brain of the rat (1988) (12)
Objective measurement of parkinsonian tremor. (1965) (12)
Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum (1995) (11)
The interaction of clonidine with dopamine-dependent behaviour in rodents (1977) (11)
Alterations in cerebral glutamic acid decarboxylase and3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine (2005) (11)
Clonidine in Parkinson disease. (1975) (11)
Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease. (1990) (11)
Tyrosinase Activity in the Pigmented Cells of the Nucleus Substantiae Nigrae: II. Further Observations on Monophenolase Activity (1961) (11)
Basal ganglia outflow pathways and circling behaviour in the rat (2005) (11)
Increased [Met]enkephalin and decreased substance p in spinal cord following thermal injury to one limb (1990) (11)
Comparison of changes in locomotor activity with striatal homovanillic acid and 3,4‐dihydroxyphenylacetic acid concentrations following the bilateral intranigral injection of dopamine agonist drugs in rats (1987) (11)
Neurotransmitter Function—Basic and Clinical Aspects (1978) (11)
Visual hallucinations and palinopsia due to an occipital lobe tuberculoma (1999) (11)
The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias). (1975) (11)
Age-related decreases in the concentration of Met-and Leu-enkephalin and neurotensin in the basal ganglia of rats (1987) (11)
Communication in Parkinson's Disease (1985) (11)
An autoradiographic study of the differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on striatal and extrastriatal D-1 and D-2 dopamine receptors in the rat (1994) (11)
Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration. (1983) (11)
Sustained-release levodopa in Parkinsonism. (1973) (11)
Psychological function in spasmodic dysphonia before and after treatment with Botulinum Toxin (1998) (11)
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment (1985) (11)
Lisuride in the treatment of myoclonus. (1986) (11)
Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain (2005) (11)
Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. (1983) (11)
Myoclonus in the rat induced by p,p'-DDT and the role of altered monoamine function (1985) (10)
Dopamine mediated circling behaviour is modulated by lesions of the ventromedial nucleus of the thalamus [proceedings]. (1979) (10)
Intrafamilial correlation in idiopathic torsion dystonia (1991) (10)
The Focal Dystonias (1982) (10)
Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets (1989) (10)
25 – Electromyography of neck muscles and treatment in spasmodic torticollis (1990) (10)
The neurotoxic actions of 6-hydroxydopamine infused into the rat substantia nigra (1986) (10)
Gamma-aminobutyric acid and basal ganglia outflow pathways. (1984) (10)
Antagonism by propranolol of central dopamine receptor stimulation is not related to β‐adrenergic blockade (1979) (10)
GABA and movement disorders. (1981) (10)
Increased striatal acetylcholine after 14 months cis-flupenthixol treatment in rats suggests functional supersensitivity of dopamine receptors. (1982) (10)
Performance of simultaneous motor acts in normal subjects and in patients with Parkinson's disease (1985) (10)
Proceedings: Fatigue in human muscle in relation to the number and frequency of motor impulses. (1976) (10)
The effects of blocking catecholamine uptake on amphetamine‐induced circling behaviour in mice with unilateral destruction of striatal dopaminergic nerve terminals (1976) (10)
PROPRANOLOL IN PARKINSON'S DISEASE (1974) (10)
Proceedings: Behavioural and biochemical evidence for cerebral dopamine receptor blockade by metoclopramide in rodents. (1975) (10)
Bromocriptine and dopamine receptor stimulation. (1976) (10)
Two Strategies for Learning a Visually Guided Motor Task (1982) (10)
The latency of the anal reflex. (1982) (10)
Neurochemical basis of parkinsonian tremor (1984) (10)
Animal models of neuroleptic-induced acute dystonia. (1988) (10)
Spasmodic dysphonia in Gilles de la Tourette's disease. (1983) (10)
GROWTH-HORMONE RESPONSE IN PARKINSON'S DISEASE (1976) (9)
CEREBRAL ACTIVATION WITH STEREOTYPED WRITING IN PATIENTS WITH WRITERS CRAMP BEFORE AND AFTER BOTULINUM TOXIN TREATMENT - A PET STUDY (1995) (9)
Correlation of [3H]5-hydroxytryptamine (5HT) binding to brain stem preparations and the production and prevention of myoclonus in guinea pig by 5HT agonists and antagonists. (1984) (9)
Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the rat (2004) (9)
Botulinum toxin in torticollis (1989) (9)
Neurological Disorders in the Elderly (1983) (9)
Intracranial complications of middle ear disease and mastoid surgery. (1969) (9)
Inhibition of circling behavior by neuroleptic drugs in mice with unilateral 6-hydroxydopamine lesions of the striatum (1975) (9)
An introduction to the new surgery for Parkinson's disease. Past and present problems. (1997) (9)
BENZTROPINE INHIBITS TOXICITY OF MPTP IN MICE (1985) (9)
Evidence for a direct peripheral effect of adrenaline on physiological tremor in man. (1967) (9)
Temporary interruption of brain processing by an electrical or magnetic cortical shock in man (1987) (9)
Lisuride in the treatment of Parkinsonism (1980) (9)
Trans-callosal effects on motor cortical excitability in man (1990) (9)
Differential ability of selective and non-selective dopamine agonists to induce climbing in the rat indicates the involvement of both D-1 and D-2 receptors in this behaviour (2005) (8)
Inhibition of turning behaviour by clozapine in mice with unilateral destruction of dopaminergic nerve terminals (1975) (8)
Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration (1992) (8)
Essential tremor associated with paroxysmal kinesigenic dystonia (1991) (8)
DIRECT ESTIMATION OF CORTICOSPINAL TRACT CONDUCTION-VELOCITY IN MAN (1985) (8)
EVIDENCE FOR AN IPSILATERAL CORTICOSPINAL PATHWAY TO FOREARM MUSCLES IN MAN (1983) (8)
A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration (2004) (8)
Movement disorder society symposium on cortical‐asal ganglionic degeneration (CBGD) and its relationship to other asymmetrical cortical degeneration syndromes (ACDs) washington, D. C. October 25–26, 1995 (1996) (8)
The mammalian pons, olive and pyramid (1965) (8)
Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion (2005) (8)
Treatments for torticollis. (1989) (8)
Toxins, genetics, and Parkinson's disease: the role of N-acetyltransferase 2. (1999) (8)
HABITUATION OF THE HUMAN LONG LATENCY STRETCH REFLEX (1985) (8)
Clinical evaluation of debrisoquin in the treatment of hypertension. (1968) (8)
Parkinson's Disease: A Self-Help Guide (1998) (8)
What should neurologists do? (1981) (8)
MANUAL MOTOR FUNCTION IN A DEAFFERENTED MAN (1981) (8)
Motor activity and the outputs of the basal ganglia (1981) (8)
Plasma propranolol in essential tremor (1982) (8)
The Assessment and therapy of parkinsonism (1990) (8)
Tiapride in 12 Huntington's disease patients. (1985) (8)
Tyrosinase Activity in the Pigmented Cells of the Nucleus Substantiae Nigrae. I. Monophenolase and Diphenolase Activity (1961) (7)
PS-56-5 Evidence for enhanced sensorimotor cortex excitability in dystonia (1995) (7)
Electromyographical differentiation of the components of perioral movements induced by SKF 38393 and physostigmine in the rat (2005) (7)
Atropine manipulation of elevated cerebral dopamine turnover caused by haloperidol or substituted benzamide drugs (1978) (7)
Oxyferriscorbone elevates the total iron content of blood but not brain (1989) (7)
OBSERVATIONS ON CHLORALOSE‐INDUCED MYOCLONUS IN GUINEA‐PIGS (1980) (7)
Insulin-induced hypoglycaemia does not abolish chorea. (1982) (7)
Towards nosology of gait disorders. Descriptive Classification. (1997) (7)
Hypophysectomy does not prevent increased cerebral dopamine turnover following sulpiride administration (1983) (7)
Possible Neuronal Mechanisms Involved in the Production of the Disinhibitory Action of Sulpiride (1981) (7)
Dopamine receptor binding sites in the rat superior colliculus (1984) (7)
Psychogenic problems associated with dystonia. (1995) (7)
Chronic Administration Does Not Alter the Pharmacokinetic Profile of l‐Dopa in the Rat (1993) (7)
Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: relevance to brain biochemistry in schizophrenia. (1980) (7)
AMANTADINE-INDUCED HEART FAILURE (1977) (7)
CEREBRAL ACTIVATION WITH PERFORMING AND IMAGINING MOVEMENT IN IDIOPATHIC TORSION DYSTONIA (ITD) - A PET STUDY (1994) (7)
Modification of the L-DOPA reversal of reserpine akinesia by inhibitors of dopamine-beta-hydroxylase. (1976) (7)
Rotation produced by electrolytic lesions of the superior cerebellar peduncle in rats modifying other forms of circling behavior (1976) (7)
L-DOPA esters as potential prodrugs. II: Chemical and enzymatic hydrolysis (1985) (7)
5-HT-mediated myoclonus in the guinea pig as a model of brainstem 5-HT and tryptamine receptor action. (1986) (7)
1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset. (1990) (7)
Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. (1987) (7)
The influence of piribedil (ET495) on components of locomotor activity. (1975) (7)
Spinal rigidity following acute myelitis (1997) (7)
Behavioural changes induced by N,N-dimethyltryptamine in rodents [proceedings]. (1978) (7)
In reply: fetal brain grafts and Parkinson's disease. (1990) (6)
Interference by alphamethylparatyrosine with three procedures for assay of cerebral catecholamines (1975) (6)
Behavioural effects mediated by unilateral nigral dopamine receptor stimulation in the rat (2004) (6)
A redox reaction between MPP+ and MPDP+ to produce superoxide radicals does not impair mitochondrial function. (1991) (6)
Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum. (1992) (6)
Absence of the first component of the long-latency human stretch reflex in a thumb muscle when it is used as an antagonist [proceedings]. (1976) (6)
ACTION OF THE ANTAGONIST MUSCLE DURING FAST LIMB MOVEMENTS IN MAN (1981) (6)
Interpretation of changes in apomorphine-induced stereotyped behaviour in rats receiving continuous administration of trifluoperazine for 15 months (1984) (6)
The apraxias are higher-order defects of sensorimotor integration. (2007) (6)
A COMPARISON OF THE EFFECTS OF CATHODAL, AND ANODAL STIMULATION OF THE HUMAN MOTOR CORTEX THROUGH THE INTACT SCALP (1987) (6)
Motor function of basal ganglia (1984) (6)
The emotion of pain and its chemistry. (1979) (6)
Neuroleptic-induced tardive dyskinesia. (1987) (6)
ESSENTIAL TREMOR. AUTHOR'S REPLY (1992) (6)
Thomas Willis's Oxford Lectures (1981) (6)
Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D 2 and D 3 receptors in rat brain (6)
[125I] Spiperone is not a useful ligand for studying the CHAPS solubilized dopamine D‐2 receptor from rat striatum (1986) (6)
MAGNETIC RESONANCE IMAGING TO DETECT DEEP BASAL GANGLIA LESIONS IN HEMIDYSTONIA THAT ARE MISSED BY COMPUTERISED TOMOGRAPHY (1985) (5)
OXIDATIVE ENZYMES RESPONSIBLE FOR THE CONVERSION OF 3,4-DIHYDROXYPHENYLALANINE TO MELANIN IN THE SMALL INTESTINE OF RODENTS (1966) (5)
A CENTENNIAL BIBLIOGRAPHY OF HUNTINGTON'S CHOREA 1872-1972 (1975) (5)
Comparing biological potencies of Botox and Dysport with a mouse diaphragm model may mislead (1998) (5)
Brainstem encephalopathy with stimulus‐sensitive myoclonus leading to respiratory arrest, but with recovery: A description of two cases and review of the literature (1996) (5)
Pergolide in the treatment of Parkinson's disease. (1984) (5)
Transient contraversive turning produced by unilateral lesions in the region of the locus coeruleus. (1975) (5)
DOSE-DEPENDENT LOCOMOTOR EFFECTS OF BROMOCRIPTINE IN ANIMALS AND MAN — ARE SOME OF ITS ACTIONS DUE TO METABOLITES? (1979) (5)
The interaction of substituted benzamides with brain benzodiazepine binding sites in vitro (1988) (5)
Alterations in cerebral dopamine function caused by administration ofcis- ortrans-flupenthixol for up to 18 months (1983) (5)
CONTRASTING EFFECTS OF MUSCLE STRETCH ON THE RESPONSE TO MAGNETIC AND ELECTRICAL CORTICAL STIMULATION IN MAN (1989) (5)
Chapter 5 – Antiparkinsonian and antidyskinetic drugs (1982) (5)
The influence of aromatic substituents on the binding of substituted benzamides to dopamine D‐2 receptors: congruent QSAR and MEP analyses (1987) (5)
The dancing larynx—a variant of palatal tremor? (1999) (5)
A new society, a new journal, and a new medium (1986) (5)
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats. (1990) (5)
GABA mediated circling from substantia nigra (1980) (5)
3‐Methoxy‐4‐hydroxyphenylglycol sulphate (MOPEG‐SO4) as an index of cerebral noradrenaline turnover following depletion of transmitter stores in the rat (1978) (5)
Proceedings: Is metoclopramide a directly acting dopamine receptor antagonist? (1976) (5)
Relationship between plasma propranolol levels and the clinical suppression of essential tremor [proceedings]. (1979) (5)
Servo action in human posture [proceedings]. (1976) (5)
Case 2, 1991: Unusual tremor, myoclonus, and a limping gait (1991) (5)
INTERACTION BETWEEN ELECTRICAL AND MAGNETIC STIMULATION OF THE HUMAN-BRAIN (1987) (5)
CAN THE CEREBELLUM BE STIMULATED THROUGH THE INTACT SCALP IN MAN (1990) (5)
Definition of the In‐vivo Accumulation of [3H]spiperone in Brain using Haloperidol and Sulpiride to Determine Functional Dopamine Receptor Occupation (1988) (5)
METOPROLOL IN ESSENTIAL TREMOR (1980) (4)
The effect of chronic administration and withdrawal of amphetamine on cerebral dopamine receptor sensitivity (1978) (4)
Effect of angiotensin on urea reabsorption in man. (1967) (4)
Sequential bilateral transplantation in Parkinson's (1999) (4)
Chronic administration does not alter the accumulation of L‐dopa into muscle (2004) (4)
Altered serotoninergic activity in mouse brain induced by clonazepam [proceedings]. (1978) (4)
Conversion "v" profiles in torticollis. (1989) (4)
p,p'-DDT-induced myoclonus in the rat and its application as an animal model of 5-HT-sensitive action myoclonus. (1986) (4)
Parkinson's disease: a self help guide for patients and their carers (1998) (4)
IMPAIRED ACTIVATION OF MESIAL FRONTAL-CORTEX DURING SELF-PACED MOVEMENTS IN PARKINSONS-DISEASE (1994) (4)
Fifty Neurological Cases from the National Hospital (1998) (4)
Some initial animal and human pharmacological studies with benapryzine (BRL 1288) (1973) (4)
Feedback control of voluntary movements in man. (1978) (4)
EFFECT OF SUBTHRESHOLD MOTOR CORTICAL SHOCKS ON THE HUMAN SPINAL MONO-SYNAPTIC REFLEX (1983) (4)
CORTICAL PROJECTIONS TO PROXIMAL ARM MUSCLES IN MAN (1989) (4)
Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat (1987) (4)
Advances in the Management of Parkinsons Disease (1976) (4)
Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs (2005) (4)
Chairman's Conclusion (1994) (4)
Adrenoreceptor antagonists in essential tremor (4)
THE DEVELOPMENT OF PIGMENTATION AND ENZYME ACTIVITY IN THE NUCLEUS SUBSTANTIAE NIGRAE OF THE CAT. (1965) (4)
Clinical Neuroepidemiology (1981) (4)
RESPONSE TO REBREATHING IN THE DIAGNOSIS OF CARDIORESPIRATORY FAILURE (1966) (4)
Amantadine in migraine. (1972) (4)
Dopamine-mediated circling behaviour does not involve the nigro-tectal pathway (1979) (4)
Proceedings: Clonazepam-induced changes in 5-hydroxytryptamine (5-HT) metabolism in aminals and man. (1975) (4)
Blepharospasm-oromandibular dystonia syndrom (1976) (4)
Renal and pressor actions of angiotensin in salt loaded and depleted rabbits (1967) (4)
Latent idiopathic torsion dystonia provoked by thyrotoxicosis. (1981) (4)
Proceedings: The effect of cholinergic and anticholinergic drugs on rotational behaviour in mice with destruction of one nigrostriatal pathway. (1975) (4)
Problems in dyskinesias (1981) (4)
Monitoring Spinal Motor Tract Function Using Cortical Stimulation: A Preliminary Report (1985) (4)
MOTOR CORTICAL EXCITABILITY IN PARKINSONS-DISEASE (1984) (3)
Supersensitivity of cerebral dopamine receptors during on-going chronic (six months) administration of trifluoperazine to rats [proceedings]. (1978) (3)
Multivariate statistical analysis of L-dopa esters as potential anti-parkinsonian prodrugs. (1987) (3)
Motor Slowness in Parkinson’s Disease (1993) (3)
Managing extrapyramidal disorders. (1980) (3)
The Stretch Reflex: Human Spinal and Long-Loop Reflexes (1984) (3)
Aids to the Examination of the Peripheral Nervous System. The Editorial Committee for the Guarantors of Brain. (1987) (3)
Regional changes in brain dopamine receptor function during six months trifluoperazine administration to rats [proceedings]. (1980) (3)
Lisuride and pergolide in Parkinson's disease. (1983) (3)
Abstracts. Third international dystonia symposium (1997) (3)
D1 or D2 receptor-induced purposeless chewing in rats is differentially modulated by cholinergic drugs. (1989) (3)
Nicotine nasal spray is not reliable treatment for blepharospasm: Results of a pilot study (1998) (3)
ELECTRICAL CORTICAL STIMULATION, A NEW TECHNIQUE IN EVALUATING (1986) (3)
Non-invasive stimulation of brain and spinal cord : fundamentals and clinical applications : proceedings of a workshop held in Sorrento, Italy, May 24-29, 1987 (1988) (3)
Reflex sympathetic dystrophy (1995) (3)
Critical role of midbrain reticular formation in the expression of dopamine-mediated circling behaviour. (1981) (3)
Effects of discontinuous drug administration on the development of dopamine receptor supersensitivity during chronic trifluoperazine or cis-flupenthixol administration to rats (2004) (3)
Estrogens and dyskinesia [letter] (1984) (3)
SELF-INITIATED VS EXTERNALLY-TRIGGERED ACTIONS - THE EFFECTS OF STIMULUS PREDICTABILITY STUDIED WITH POSITRON EMISSION TOMOGRAPHY (1995) (3)
METOCLOPRAMIDE IN PARKINSONISM (1975) (3)
Hyperprolactinaemia does not alter specific striatal 3H-spiperone binding in the rat. (1986) (3)
10 – The integrity of the dopaminergic system in patients with multiple system atrophy and pure autonomic failure studied with PET (1990) (3)
Chronic trifluoperazine treatment does not induce lipid peroxidation in the rat cortex (1987) (3)
Behavioural and biochemical effects of chronic reduction of cerebral noradrenaline receptor stimulation (1977) (3)
OBSERVATIONS ON THE MECHANISM OF LONG-LASTING RECIPROCAL INHIBITION IN THE HUMAN FOREARM (1985) (3)
Studies on the normal and disordered human motor cortex. (1982) (3)
The absence of sodium ions does not explain the failure of sulpiride to inhibit, in vitro, rat striatal dopamine‐sensitive adenylate cyclase (1981) (3)
[Percutaneous electric and magnetic stimulation of the motor cortex in man. Physiological aspects and clinical applications]. (1989) (3)
The work of neurologists. (1989) (3)
Brain Neurotransmitters and Receptors in Aging and Age-related Disorders (Aging Vol. 17) (1982) (3)
Lack of effect of intranigral administration of a dopamine analogue, (±)-3-(3-hydroxyphenyl)-N,n-propylpiperidine [(±)-3-PPP], on nigrostriatal dopamine neurones (1985) (3)
LONG-LASTING INHIBITION OF THE FLEXOR MONO-SYNAPTIC REFLEX FROM EXTENSOR MUSCLES IN THE HUMAN FOREARM (1982) (3)
Olivopontocerebellar atrophy and multiple system atrophy: Clinical follow‐up of 10 patients studied with PET (1998) (3)
Assessing tremor severnty (3)
TREMORS AND TREMOROGENIC AGENTS (1973) (3)
BASAL GANGLIA NEUROPEPTIDE ALTERATIONS IN PARKINSON??S DISEASE AND CONTROLS BEARING LEWY BODIES (1992) (3)
HUMAN SACCADIC REACTION-TIME IS DELAYED BY TRANSCRANIAL MAGNETIC STIMULATION (1991) (3)
A strategy for measuring the therapeutic properties of new antiparkinsonian drugs, such as +PHNO, in patients with on-off fluctuations. (1989) (3)
Functional increase in striatal dopaminergic activity following continuous long-term treatment with trifluoperazine (1984) (3)
Toxic myoclonus. (1986) (3)
Muscle spasms associated with Sudeck's atrophy after injury (1984) (3)
Evidence for enhanced sensorimotor cortex excitability in dystonia (1997) (3)
Effect of chronic trifluoperazine administration and subsequent withdrawal on the production and persistence of perioral behaviours in two rat strains (2005) (3)
Announcing the “Videotapes to the Editor” section (1988) (3)
THE CORTICOMOTONEURON CONNECTION IS NORMAL IN PARKINSONS-DISEASE (1984) (3)
Involuntary Movements other Than Parkinsonism (1973) (3)
5‐HYDROXYTRYPTAMINE AND MYOCLONUS INDUCED BY 1,2‐DI‐HYDROXYBENZENE (CATECHOL) IN THE GUINEA‐PIG (1979) (2)
Dr. S. A. Kinnier Wilson (1887‐1937) (1988) (2)
[Pharmacologic, surgical and infiltration of botulin toxin treatment in blepharospasm]. (1989) (2)
The influence of the experimental conditions on the renal response to angiotensin in the rat (1967) (2)
EFFECTS OF MAGNETIC BRAIN-STIMULATION ON WRIST TREMOR IN PATIENTS WITH PARKINSONS-DISEASE (1991) (2)
Drop attacks. (1995) (2)
Behavioural effects of allylglycine (2-amino-4-pentenoic acid) and 2-keto-4-pentenoic acid following focal injection into the rat cerebellum and caudate nucleus [proceedings]. (1978) (2)
Proceedings: Differences in circling responses following electrolytic and 6-hydroxydopamine lesions of the nigro-striatal pathway. (1975) (2)
Café-au-lait spots and vitiligo in Parkinson's disease. (1972) (2)
Progressive myoclonus and histidinaemia (1991) (2)
Transplantation of embryonic mesencephalic and medullary raphe neurons to the neostriatum of rats with unilateral 6-hydroxydopamine lesions (1992) (2)
PATTERNED ELECTROMYOGRAPHIC RESPONSES TO GALVANIC EAR STIMULATION IN MAN (1990) (2)
Proceedings: The mechanism of the effect of dopamine-beta-hydroxylase inhibitor FLA-63 on the L-DOPA reversal of reserpine akinesia. (1975) (2)
Iris pigmentation in idiopathic dystonia. (1982) (2)
Movement disorders 1 and 2 (1995) (2)
Prevention and Treatment of Cerebrovascular Disease (1987) (2)
Histochemical Demonstration of Ascorbic Acid in the Substantia Nigra of the Cat (1962) (2)
Research report Dopamine D 3 :receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment (1996) (2)
Partial reversal of increased preproenkephalin messenger ribonucleic acid (mRNA) and decreased preprotachykinin mRNA by foetal dopamine cells in unilateral 6‐Hydroxydopamine–Lesioned rat striatum parallels functional recovery (1996) (2)
Progress in Stroke Research 1 (1980) (2)
of 23 patients a V ected by the sti V man syndrome : clinical subdivision into sti V trunk ( man ) syndrome , sti V limb syndrome , and progressive encephalomyelitis with rigidity (1998) (2)
MPTP Infusion into Rat Substantia Nigra Causes Hypokinesia and Bradykinesia which are Reversed by L-Dopa Treatment (1986) (2)
Madopar HBS: International Workshop in the 'On-Off'-Phenomenon in Parkinson's Disease New Possibilities for its Management, Agno, November 1985 (1987) (2)
EVIDENCE THAT TRANSCRANIAL MAGNETIC STIMULATION DELAYS SACCADIC EYE-MOVEMENTS BY INTERFERING WITH ACTIVITY IN OCULOMOTOR AREAS OF CORTEX IN MAN (1991) (2)
Changes in perceived heaviness in man after thumb anaesthesia are associated with corresponding changes in the degree of muscle activation [proceedings]. (1978) (2)
Striatal Inhomogeneities and Basal (1986) (2)
Substituted benzamides as dopamine antagonists (1976) (2)
Living with Huntington's Disease (A Book for Patients and Families) (1983) (2)
The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist. (1989) (2)
PROGRESS IN THE TREATMENT OF PARKINSONISM (1974) (2)
ON-OFF SYNDROME IN PARKINSON'S DISEASE AND INTRAVENOUS LEVODOPA (1982) (2)
Enhancement of stereotypy induced by nomifensine in rats during continuous chronic haloperidol treatment (1984) (2)
CENTRAL GAIN-CONTROL OF POSTURAL RESPONSES TO GALVANIC VESTIBULAR STIMULATION (1992) (2)
Superior colliculus lesions do not alter dopamine mediated circling behaviour [proceedings]. (1979) (2)
Definition of the In‐vivo Binding of [3H]Spiperone in Rat Brain Using Substituted Benzamide Drugs (1989) (2)
Platelet mitochondrial DNA in Parkinson's disease. (1994) (2)
1 – The physiology of electrical and magnetic stimulation of the human brain through the intact scalp (1990) (2)
STUDY OF CONDUCTIONS IN CENTRAL MOTOR PATHWAYS DURING NEUROLOGICAL DISEASES (1985) (2)
Neuronal filaments in Alzheimerʼs, Pickʼs, and Parkinsonʼs diseases (1987) (2)
Essential tremor (1992) (2)
News on NOS: Neuronal nitric oxide synthase as a drug target (1994) (2)
Dystomia 3. Summary and conclusions. (1998) (2)
Evidence for metabolite involvement in bromocryptine-induced circling behaviour [proceedings]. (1979) (1)
Proceedings: Biochemical evidence for the involvement of noradrenaline in motor activity produced by L-DOPA in rodents. (1975) (1)
Dopamine Hypothesis in Acute Psychosis (1981) (1)
Affinity of pyridylalkylamines for nicotinic, muscarinic and histaminic recognition sites in brain tissue preparations. (1986) (1)
Recent developments in the pharmacotherapy of major neurological dysfunction (1992) (1)
Achilles tendon reflex time (1967) (1)
Double blind trial of dogmatil in Huntington chorea and tardive dyskinesia (1985) (1)
Dopamine Neurone Destruction in Human and Animal Parkinsonism (1986) (1)
5-Hydroxytryptophan-induced behaviour in guinea-pigs: its relevance to human myoclonus [proceedings]. (1977) (1)
Dementia in Parkinson’s Disease and Central Cholinergic Function (1990) (1)
Sensitivity, efficacy and disappearance of servo action in human muscle [proceedings]. (1979) (1)
Evoked potentials in multiple system atrophy (1990) (1)
ELECTROMYOGRAPHIC RESPONSES FROM LEG MUSCLES PRODUCED BY PERCUTANEOUS ELECTRICAL-STIMULATION OVER THE LOWER SPINAL COLUMN IN MAN (1987) (1)
Lessons fromaremarkable family withdopa- responsive dystonia (1994) (1)
of Parkinson ' s disease . Amphetamines in the treatment (1)
Brain Metabolism and Cerebral Disorders (1977) (1)
Lisuride and Proterguride Reverse MPTP-Induced Parkinsonism in the Common Marmoset (1990) (1)
Facets of Akinesia in Parkinson’s Disease (1987) (1)
The Involvement of the Superior Colliculus and Midbrain Reticular Formation in the Expression of Circling Behaviour (1982) (1)
MULTIPLE FIRING OF SPINAL MOTONEURONS PRODUCED BY SINGLE ANODAL ELECTRICAL SHOCKS TO HUMAN MOTOR CORTEX (1986) (1)
The binding of [3H]N-(chloroethyl)-norapomorphine to rat striatal membranes. (1984) (1)
Advances in the management of parkinson's disease. (1976) (1)
Neuroleptic‐induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors (1981) (1)
Plasma HVA levels following debrisoquine administration do not reflect cerebral dopamine loss in early Parkinson's disease. (1994) (1)
Movement of the human thumb is not achieved by re resetting its spring constants (1981) (1)
Paternal age effect in isolated juvenile torison dystonia. (1976) (1)
Frontal activation during self-initiated finger movements and externally paced movements triggered by predictable and unpredictable stimuli (1996) (1)
Sickness due to levodopa‐induced neck dyskinesias in Parkinson's disease (1991) (1)
Presenile dementia. (1972) (1)
DOPAMINERGIC FUNCTION IN RELATIVES OF PARKINSONS-DISEASE PATIENTS - A CLINICAL AND PET STUDY (1995) (1)
Abnormal Feedback and Movement Disorders in Man, with Particular Reference to Cortical Myoclonus (1985) (1)
Olfactory threshold inParkinson's disease (1987) (1)
Substituted benzamides as dopamine antagonists [proceedings]. (1976) (1)
Taurine By R. Huxtable and A. Barbeau (eds.), xiv + 398 pages, 123 illustrations, 76 tables, Raven Press, New York, N.Y., 1976, US$ 29.50 (1977) (1)
Letter: L 5-Hydroxytryptophan and mood. (1975) (1)
BROMOCRIPTINE IN PARKINSONISM (1975) (1)
Iris pigementation in idiopathic dystonia (1982) (1)
RESPONSE OF THE HUMAN LONG THUMB FLEXOR TO DOUBLE STRETCHES (1980) (1)
Parkinsonian Syndrome Caused by 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Man and Animals (1987) (1)
Cortical muscarinic receptors in demented patients with Alzheimer's disease or Parkinson's disease. (1989) (1)
Reviews of neuroscience, vol. 2 by S. Ehrenpreis and I. J. Kopin (Series Editors), ix + 270 pages, 19 illustrations, 8 tables, Raven Press, New York, 1976, US$ 24.00 (1977) (1)
ROLE OF DOPAMINE IN ROTATIONAL BEHAVIOR PRODUCED BY UNILATERAL LESIONS OF LOCUS COERULEUS (1975) (1)
The cause of blepharospasm is unknown in most cases. (1990) (1)
LETTERS TO THE EDITOR (1959) (1)
Introducing the “what is it?” section (1986) (1)
New Perspectives in Cerebral Localization (1982) (1)
Dopamine and somatostatin modulated adenylate cyclase activity in the rat caudate-putamen following unilateral cortical ablation (2004) (1)
Parkinsonism: Physiology, Pharmacology and Treatment. (1971) (1)
Central deopaminergic receptor supersensitivity and its relevance to Parkinson's disease. (1977) (1)
Parkinson's disease and the parkinsonian syndrome (1972) (1)
MATTERS ARISING (1994) (1)
Physiology and Pathophysiology of Reciprocal Inhibition in the Human Forearm (1987) (1)
Interactions of substituted benzamide drugs with cerebral dopamine pathways [proceedings]. (1977) (1)
ADVANCES IN NEUROLOGY Vol. 3. PROGRESS IN THE TREATMENT OF PARKINSONISM (1976) (1)
Observations on the facilitation of muscle responses to cortical stimulation by voluntary effort (1990) (1)
Terguride, a Dopamine Partial Agonist for the Treatment of Parkinson’s Disease (1990) (1)
THE INFLUENCE OF VISION ON THE ACCURACY OF REACHING MOVEMENTS IN PATIENTS WITH CEREBELLAR DISEASE (1992) (1)
Letter: Propranolol in Parkinson's disease. (1974) (1)
CHOLINERGIC MARKERS IN ALZHEIMERS-DISEASE AND PARKINSONS-DISEASE (1990) (0)
Amyotrophic Lateral Sclerosis (1981) (0)
BOOK REVIEWS (1993) (0)
The neural control of behavior (1971) (0)
3-42-06 The role of I-dopa pharmacodynamic in the pathogenesis of motor fluctuations (1997) (0)
Pseudoseizures (1984) (0)
Motor Function in a Patient with Bilateral Globus Pallidus Lesions of the (1995) (0)
Proceedings of the Physiological Society, 27‐28 March 1987, University College London/Middlesex Meeting: Communications (0)
Effect ofspeed ofmuscle contraction on physiological tremorinnormal subjects andin patients withthyrotoxicosis andmyxoedema (1970) (0)
17.1 – Surgical approaches to the dyskinesias: foreword (1981) (0)
Dementia with Lewy Bodies: Relevance of Lewy bodies to alterations in oxidative stress in Lewy body dementia and Parkinson's disease (1996) (0)
levodopa-induced dyskinesias . in Parkinson ' s disease and Metoclopramide and pimozide (0)
THE NATURE OF APRAXIA IN CORTICOBASAL DEGENERATION - REPLY (1994) (0)
Brain-pituitary-adrenal interrelationships (International symposium on brain-pituitary-adrenal interrelationships, Cincinnati, Ohio, 14–16 June, 1972), by A. Brodish and E. S. Redgate (Eds.), xii + 340 pages, 182 illustrations, 29 tables, Karger, Basel, 1973, SFr 146.00, US $45.30, DM 132.00, £18.55 (1975) (0)
Treatment of Diseases of Nerve and Muscle (1987) (0)
Alpha‐tocopherol levels in Parkinsonian brains (1993) (0)
Hypophysectomy may non-selectively alter pharmacokinetic parameters to enhance the ability of haloperidol to increase striatal dopamine receptor density in the rat. (1986) (0)
BASICITY, LIPOPHILICITY, AND LACK OF RECEPTOR INTERACTION OF N-AMINOALKYLBENZAMIDES AND N-AMINOALKYL-O-ANISAMIDES AS MODEL COMPOUNDS OF DOPAMINE ANTAGONISTS (1983) (0)
Book reviews (1982) (0)
49. 99Tcm-HMPAO rCBF SPECT in corticobasal degeneration (1992) (0)
Huntington's Chorea (1982) (0)
Reversal of Pharmacological and Biochemical Effects of Neuroleptic Drugs on Chronic Administration (1980) (0)
AND CENTRAL CHOLINERGIC FUNCTION (1990) (0)
Familial paroxysmal dystonia induced by exercise GT PLANT , * (0)
Alzheimer ' s histopathology . Alien hand sign in association with (0)
Alpha-methyldopamine as a dopaminergic agonist. (1975) (0)
The physiological basis of ataxia. (1975) (0)
Narcolepsy (1979) (0)
Letter: Chorea and torsion in parkinsonism. (1976) (0)
Drug Treatment of Infections of the Nervous System (1987) (0)
Myotonic Dystrophy (1980) (0)
Botulinum Toxin Treatment of Spasmodic Torticollis: Effects on Psychosocial Function (1993) (0)
BOOK REVIEWS (1994) (0)
1-methyl-4-phenyl-1,2,3,6-tetradropyridine-induced parkinsonism in the commonmarmoset (1984) (0)
Neurology of Hereditary Metabolic Diseases of Children (1984) (0)
PATHO-PHYSIOLOGY OF CRANIAL DYSTONIA (1985) (0)
Theuse ofbotulinum toxin inthetreatmentof adductor spasmodic dysphonia (1993) (0)
Atypical presentations of DRD mutations (1997) (0)
The Mode of Action of Acupuncture in Bronchial Asthma (1977) (0)
The effect of carbidopa on the phannacokinetics of L-dihydroxyphenylalanine in the rat (1990) (0)
A Stereotaxiv Atlas of the Albino Mouse Forebrain (1980) (0)
Neuronal Compensation and Age as Factors Affecting MPTP-induced Parkinsonism in the Common Marmoset (1988) (0)
Neurofibromatosis (Von Recklinghausen Disease) Genetics, Cell Biology and Biochemistry. (Advances in Neurology, Vol. 29.) (1982) (0)
Changes in motor cortex organization in Parkinson's disease (1995) (0)
Immunosuppressant and Cytotoxic Drugs, Toxic and Metabolic Disorders (1987) (0)
POSTURAL RESPONSES TO GALVANIC VESTIBULAR STIMULATION IN PATIENTS WITH PARKINSONS-DISEASE (1992) (0)
otor inhibition from the brainstem is normal in torsion dystonia during REM sleep (0)
Rapidelbow movementsinpatients withtorsion dystonia (1989) (0)
Chronic amphetamine administration and central dopamine receptor sensitivity [proceedings]. (1977) (0)
Case 50(from the archives—1877) (1998) (0)
Characteristics of the Solubilised D-2 Dopamine Receptor from Rat Striatum (1986) (0)
Regulatory Peptides of Gut and Brain (1983) (0)
Theeffect ofpostureon thenormaland pathological auditory startle reflex (1991) (0)
Workshop Cortical and spinal stimulationCharacteristics of spinal cord motor tract potentials evoked by stimulation during spinal cord surgery (1985) (0)
Drugs in Neuroendocrinology (1987) (0)
disease . polymorphism in familial Parkinson ' s Debrisoquine hydroxylase gene (0)
FUNCTIONS OF THE BASAL GANGLIA. AUTHORS' REPLY (1995) (0)
PSM volume 11 issue 4 Cover and Front matter (1981) (0)
ALTERATIONS IN IRON CONTENT IN PARKINSONIAN BRAIN (1988) (0)
Disorders of Sleep and Wakefulness (1987) (0)
EFFECT OF EXPERIMENTAL-ISCHEMIA ON CEREBRAL MONO-AMINE LEVELS IN GERBIL BRAIN (1978) (0)
Clinical relevance of neuropeptide research. (1986) (0)
PERCUTANEOUS ELECTRICAL AND MAGNETIC STIMULATION OF THE HUMAN MOTOR CORTEX - PHYSIOLOGICAL DATA AND CLINICAL-APPLICATIONS (1989) (0)
Substituted Benzamide Drugs as Selective Agents for Distinguishing Cerebral Dopamine Receptor Sub-types (1983) (0)
Essential tremor. (1992) (0)
Methods in brain research By P. B. Bradley (ed.), ix + 557 pages, 153 illustrations, 20 tables, John Wiley and Sons, London, 1975, £ 18.00 (1976) (0)
Erratum (1996) (0)
Enhanced GABA function in the angular complex (lateral periaqueductal grey matter and adjacent reticular formation) alters the postural component of striatal- or nigral-derived circling (2004) (0)
DYNAMIC NEUROSCIENCE. ITS APPLICATION TO BRAIN DISORDERS (1977) (0)
Reply (1996) (0)
[Hung-up reflexes in Huntington disease. Study of a minor sign]. (1984) (0)
CUTANEOUS CONDITIONING OF THE STRETCH REFLEX IN MUSCLES OF THE HUMAN FOREARM (1992) (0)
Central properties of alpha-allophanyl-alpha-allyl-gamma-valerolactone (valofan) [proceedings]. (1979) (0)
Essential tremor and PD (1993) (0)
Fluctuations in response to L-dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover. (1989) (0)
Biochemistry and neurology : proceedings of a conference organized by the Neurochemical Group of the Biochemical Society and held at Nottingham University, April 1975 (1976) (0)
RELATIONSHIP BETWEEN EARLY AUTOMATIC AND LATE VOLUNTARY COMPENSATORY RESPONSES TO MUSCLE STRETCH IN THE LONG FLEXOR OF THE HUMAN THUMB (1979) (0)
Biochemistry of Ataxia (1973) (0)
in cortical myoclonus . somatosensory evoked potentials On the significance of giant (0)
The Pathophysiology of Chorea, Tics and Dystonia (1985) (0)
2545 – APPARENT DOPAMINE RECEPTOR BLOCKADE BY SUBSTITUTED BENZAMIDE DRUGS (1978) (0)
FETAL BRAIN GRAFTS AND PARKINSONS-DISEASE - RESPONSE (1990) (0)
Hughlings Jackson on Psychiatry (1984) (0)
Editorial Board (1985) (0)
Alien handsign inassociation withAlzheimer's histopathology (1993) (0)
Comparison ofexecutive andvisuospatial memoryfunction inHuntington's disease and dementia ofAlzheimer typematched fordegree of dementia (1995) (0)
Treatment of Disorders Involving the Autonomic Nervous System (1987) (0)
Sequence ofthesuperoxide dismutase 1(SOD1) gene infamilial Parkinson's disease (1995) (0)
Deprenyl inthemanagementofresponsefluctuations inpatients withParkinson's disease on levodopa (1980) (0)
Dementia. A Clinical Approach (1984) (0)
823 – ROTATIONAL BEHAVIOUR IN RATS WITH UNILATERAL LESIONS OF THE CENTRAL NORADRENERGIC PATHWAY (1977) (0)
ON THE MECHANISMS OF EXTRAPYRAMIDAL REACTIONS INDUCED BY NEUROLEPTIC DRUGS (1979) (0)
Alterations in striatal preprotachykinin and nigral tyrosine hydroxylase mrna in tetrahydrobiopterin-deficient mice (1997) (0)
Clinical presentation and pharmacological therapy in cortico-basal ganglionic degeneration (1996) (0)
The relationship between early automatic and late voluntary compensatory responses to muscle stretch in the long flexor of the human thumb [proceedings]. (1979) (0)
ADVANCES IN NEUROLOGY Vol. 5. SECOND CANADIAN-AMERICAN CONFERENCE ON PARKINSON'S DISEASE (1976) (0)
824 – CHOLINERGIC INFLUENCE ON DOPAMINE-DEPENDENT TURNING BEHAVIOUR IN RODENTS (1977) (0)
Cost of brain disorders (1992) (0)
M Journal of Neural Transmission Synergism of the Ampa-antagonist Nbqx and the Nmda-antagonist Cpp with L-dopa in Models of Parkinson's Disease (0)
spinal enlargements . Magnetic stimulation over the (0)
Clinical features and natural history of adult-onset predominantly axial dystonia (1997) (0)
Short report Tyrosine hydroxylase and levodopa responsive dystonia (2004) (0)
Proceedings: A primate model of acute dystonic reaction to neuroleptics. (1976) (0)
Metoclopramide andpimozide inParkinson's disease andlevodopa-induced dyskinesias (1975) (0)
Drugs and the Nervous System (1987) (0)
Mechanisms of Cutaneous Sensation (1982) (0)
CHANGES IN PERCEIVED HEAVINESS IN MAN AFTER THUMB ANESTHESIA ARE ASSOCIATED WITH CORRESPONDING CHANGES IN DEGREE OF MUSCLE ACTIVATION (1978) (0)
Neurosecretion — The final neuroendocrine pathway: (6th international symposium on neurosecretion, London, 1973), by F. Knowles and L. Vollrath (eds.), xii + 345 pages, 92 illustrations, Springer-Verlag, Berlin, Heidelberg, New York, 1974, DM 118.00, US$ 48.20 (1976) (0)
Reply (1995) (0)
Stereoselective blockade of cerebral dopamine receptors by sulpiride and sultopride [proceedings]. (1979) (0)
BOOK REVIEWS (1991) (0)
Eye Movement Disorders (1988) (0)
Parkinson ' s disease . wrist movements in patients with agonist EMG burst during rapid Scaling of the size of the first (0)
Introduction to Nervous Systems (1978) (0)
BOOK REVIEWS (1993) (0)
1-30-14 Disruption of spatial organization of gestural movements in patients with Parkinson's disease: A kinematic analysis (1997) (0)
Spontaneous Dyskinesias Amongst Psychotic Patients (1985) (0)
Functions of the basal ganglia (第23回日本神経学会総会(1982)) -- (Generating mechanisms of extrapyramidal symptoms(シンポジウム)) (1982) (0)
CENTRAL RHYTHMIC AND REGULATION CIRCULATION (1975) (0)
Headache, Pain and Raised Intracranial Pressure (1987) (0)
qualitative analysis . disease : a quantitative and Depression in Parkinson ' s (0)
disease and their partners . Sexual function in patients with Parkinson ' s (0)
Motor unit synchronisation in subjects with writer's cramp and dystonia (1996) (0)
Disorders of the Cerebellum (1981) (0)
Domperidone. (1985) (0)
British neurology: a national focus. (1994) (0)
Vitamins and the Nervous System (1987) (0)
OBSERVATIONS ON CHLORALOSE-INDUCED GUINEA-PIGS MYOCLONUS (1980) (0)
Parkinson ' s disease . Bromocriptine treatment in (0)
symptomatic dystonia with levodopa . Successful treatment of childhood onset (0)
Parkinson's disease. (1992) (0)
Editorial (0)
CEREBRAL PALSY (1997) (0)
Comparative trial ofbenzhexol, amantadine, and levodopa inthetreatment ofParkinson's disease (1974) (0)
Pathophysiology of tics, dystonia and chorea (1983) (0)
Central dopaminergic and noradrenergic components of bromocryptine-induced locomotor activity in mice [proceedings]. (1977) (0)
The incidence and nature of dysphagia following botulinum toxin injections for torticollis (1999) (0)
alpha and beta Dopamine receptors? (1976) (0)
Neurology and psychiatry (1973) (0)
Blepharospasm: areview of264patients (1988) (0)
Immunocytochemical staining of Lewy bodies with antibodies to cytoskeleton proteins. (1987) (0)
Cortical myoclonus in coeliac disease (1995) (0)
Book Review: Parkinsonism: Physiology, Pharmacology and Treatment (1971) (0)
Physiological analysis ofsimple rapid movements inpatients withcerebellar deficits (1991) (0)
EFFECTS OF CORTICAL SUBLIMINAL ELECTRICAL SHOCKS ON SPINAL NEURONS IN HUMANS (1985) (0)
820 – NORADRENALINE AS A DETERMINANT OF MOTOR ACTIVITY IN LEVODOPA REVERSAL OF DRUG-INDUCED AKINESIA (1977) (0)
The role of NAT2 in Parkinson's disease (1997) (0)
Lack of serotoninergic involvement in turning behaviour induced by a unilateral lesion of the locus coeruleus in rats [proceedings]. (1977) (0)
Interpretation of radioactive ligand binding to cerebral dopamine receptors (1981) (0)
anorexia by inhibitors in dopamine-3-hydroxylase inhibitor FLA-63 on the L-DOPA reversal of reserpine akinesia (2006) (0)
Letters Is the loss of cerebral cortical choline acetyl transferase activity in Alzbeimers disease due to degeneration of ascending cholinergic nerve celis ? (0)
5-HYDROXYTRYPTAMINE MODULATION OF BRAIN DOPAMINE FUNCTION: IMPLICATIONS FOR THE TREATMENT OF PARKINSON'S DISEASE (2006) (0)
Modulation of picrotoxin-induced forepaw myoclonus in the rat by benzodiazepines [proceedings]. (1979) (0)
Associations for treatment of exuding wounds (2001) (0)
A COMPARISON OF THE EFFECTS OF CHRONIC (SIX MONTH) ADMINISTRATION OF TRIFLUOPERAZINE AND THIORIDAZINE ON STRIATAL DOPAMINE FUNCTION IN RATS (1979) (0)
Bain and Findley Tremor ADL Scale (1993) (0)
AbstractThe role of urethral sphincter electromyography in the differential diagnosis of parkinsonism (1989) (0)
Iontophoresis and transmitter mechanisms in the mammalian central nervous system By R. W. Ryall and J. S. Kelly, 494 pages, Elsevier/North-Holland, 1978, Price not stated (1979) (0)
Neuroendocrine control By K. Yagi and S. Yoshida (eds.), xi + 394 pages, illustrated, University of Tokyo Press, Tokyo, 1973 (1975) (0)
The scaling of muscle activation and movement amplitude in Parkinson's disease (1985) (0)
A physiological approach to clinical methods (1970) (0)
Treatment of Movement Disorders (1987) (0)
Subject Index Vol. 27, Suppl 1, 1987 (1987) (0)
TREATMENT OF PARKINSONIAN TREMOR (1966) (0)
THE DURATION OF THE 1ST AGONIST EMG BURST IS NOT CONSTANT IN RAPID ARM MOVEMENTS (1984) (0)
Procedural Memory, Motor Skill and Degenerative Neurological Disease (1993) (0)
Recent Advances in Clinical Neurology Vol. 3 (1982) (0)
819 – STUDIES ON THE MECHANISM OF THE EFFECT OF INHIBITORS OF DOPAMINE B HYDROXYLASE ON THE L-DOPA REVERSAL OF RESERPINE AKINESIA (1977) (0)
Treatment ofParkinson's disease withlevodopa combined with L-alpha-methyldopa hydrazine, aninhibitor ofextracerebral DOPAdecarboxylase (1973) (0)
Insulin-induced hypoglycaemia does not abolish chorea. (1982) (0)
AN AB INITIO STUDY OF THE PYRAMIDAL AND PLANAR ISOMERS IN LI3NO3, LI3NS3, LI3PO3, LI3PS3 MOLECULES AND THE LI3SO+3 ION (1994) (0)
Olivopontocerebellar atrophy - Reply (1995) (0)
Chronic trifluoperazine administration alters the perioral movement profile in wistar but not sprague-dawley rats (1990) (0)
Essential tremor and PD - Reply from the authors (1994) (0)
Transplantation of dopamine-synthesizing cells—new therapy for Parkinson’s disease? (1989) (0)
Bromine in the lower atmosphere (1991) (0)
The usefulness of functional imaging in movement disorders: an illustrative case. (1996) (0)
MOVEMENT DISORDERS WITH CURRENT ANTIPSYCHOTIC DRUGS (1984) (0)
Editorial (0)
A Sporadic Case of the Myoclonic Form of Dentato-Rubro-Pallidoluysian Atrophy (DRPLA) in a Caucasian (1987) (0)
Parkinson ' s disease . time and the use of advance information in medication on simple and choice reaction The effect of withdrawal of dopaminergic (0)
Letter: Relief of action myoclonus by 5-hydroxytryptophan. (1974) (0)
Noteon thescoliosis ofParkinsonism (1975) (0)
Selective Actions of Substituted Benzamide Drugs on Brain Dopamine Receptors (1985) (0)
A double blind trial ofsulpiride inHuntington' s disease andtardive dyskinesia (1984) (0)
Amphetamines inthetreatment ofParkinson's disease (1975) (0)
Letter: Metoclopramide in parkinsonism. (1975) (0)
NAT2 slow acetylator phenotype is associated with familial Parkinson's disease (1997) (0)
A variant of adult-onset torsion dystonia? (0)

This paper list is powered by the following services:

Other Resources About C. David Marsden

en.wikipedia.org

What Schools Are Affiliated With C. David Marsden?

C. David Marsden is affiliated with the following schools:

C. David Marsden's Academic­Influence.com Rankings

Why Is C. David Marsden Influential?

C. David Marsden's Published Works

Published Works

Other Resources About C. David Marsden

What Schools Are Affiliated With C. David Marsden?

C. David Marsden's AcademicInfluence.com Rankings